









Review

Bioactive Compounds from *Zingiber montanum* and Their Pharmacological Activities with Focus on Zerumbone

Hari Prasad Devkota ^{1,*}, Keshav Raj Paudel ^{2,3}, Md. Mahadi Hassan ¹, Amina Ibrahim Dirar ¹, Niranjan Das ⁴, Anjana Adhikari-Devkota ¹, Javier Echeverría ⁵, Rajan Logesh ⁶, Niraj Kumar Jha ⁷, Sachin Kumar Singh ⁸, Philip M. Hansbro ^{2,3}, Yinghan Chan ⁹, Dinesh Kumar Chellappan ⁹ and Kamal Dua ^{3,10,11}

- ¹ Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo ku, Kumamoto 862-0973, Japan; mahadihassan1@gmail.com (M.M.H.); aminadirar2007@gmail.com (A.I.D.); adhikarianjana@gmail.com (A.A.-D.)
- ² School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia; KeshavRaj.Paudel@uts.edu.au (K.R.P.); Philip.Hansbro@uts.edu.au (P.M.H.)
- ³ Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; Kamal.Dua@uts.edu.au
- ⁴ Department of Chemistry, Iswar Chandra Vidyasagar College, Belonia 799155, Tripura, India; ndnsmu@gmail.com
- ⁵ Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Casilla 40, Correo 33, Santiago 9170022, Chile; javier.echeverriam@usach.cl
- ⁶ TIFAC-CORE in Herbal Drugs, Department of Pharmacognosy and Phytopharmacy, JSS College of Pharmacy (JSS Academy of Higher Education and Research), Ooty 643001, Tamil Nadu, India; rlogesh14@gmail.com
- ⁷ Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida 201310, Uttar Pradesh, India; nirajkumarjha2011@gmail.com
- ⁸ School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India; sachin.16030@lpu.co.in
- ⁹ Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia; yinghan.chan@gmail.com (Y.C.); Dinesh_Kumar@imu.edu.my (D.K.C.)
- ¹⁰ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia
- ¹¹ Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Sydney, NSW 2007, Australia
- * Correspondence: devkotah@kumamoto-u.ac.jp



Citation: Devkota, H.P.; Paudel, K.R.; Hassan, M.M.; Dirar, A.I.; Das, N.; Adhikari-Devkota, A.; Echeverría, J.; Logesh, R.; Jha, N.K.; Singh, S.K.; et al. Bioactive Compounds from *Zingiber montanum* and Their Pharmacological Activities with Focus on Zerumbone. *Appl. Sci.* **2021**, *11*, 10205. <https://doi.org/10.3390/app112110205>

Academic Editor: Ana M. L. Seca

Received: 14 August 2021

Accepted: 25 October 2021

Published: 31 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The genus *Zingiber* consists of about 85 species and many of these species are used as food, spices, and medicines. One of the species, *Zingiber montanum* (J. Koenig) Link ex A. Dietr. is native to Southeast Asia and has been extensively used as traditional medicines and food. The aim of this review was to collect and critically analyze the scientific information about the bioactive compounds and pharmacological activities of *Z. montanum* with focus on one of the main components, zerumbone (ZER). Various studies have reported the analysis of volatile constituents of the essential oils from *Z. montanum*. Similarly, many phenylbutanoids, flavonoids and terpenes were also isolated from rhizomes. These essential oils, extracts and compounds showed potent antimicrobial, anti-inflammatory and antioxidant activities among others. Zerumbone has been studied widely for its anticancer, anti-inflammatory, and other pharmacological activities. Future studies should focus on the exploration of various pharmacological activities of other compounds including phenylbutanoids and flavonoids. Bioassay guided isolation may result in the separation of other active components from the extracts. *Z. montanum* could be a promising source for the development of pharmaceutical products and functional foods.

Keywords: *Zingiber montanum*; *Zingiber cassumunar*; zerumbone; anticancer; anti-inflammatory

1. Introduction

The Zingiberaceae family consists of about 50 genera and more than 1500 species which are distributed all over the world and most of them are found in Asia, Central

America, and Africa. Plants belonging to various genera of Zingiberaceae family are used as food, spice and medicines in many parts of the world [1]. One of the most studied genera of this family, *Zingiber* consists of about 85 species [2] and *Zingiber officinale* Roscoe. is the most commonly cultivated and used species. There are many other important species of *Zingiber* which are widely used as spices, food supplements and as crude drug in traditional medicines such as *Zingiber montanum* (J. Koenig) Link ex A. Dietr.

Zingiber montanum (Figure 1, Syns: *Amomum cassumunar* (Roxb.) Donn, *Amomum montanum* J. König, *Amomum xanthorrhiza* Roxb. ex Steud., *Cassumunar roxburghii* Colla, *Jaegera montana* (J. König) Giseke, *Zingiber anthorrhiza* Horan., *Zingiber cassumunar* Roxb., *Zingiber cassumunar* var. *palamauense* Haines, *Zingiber cassumunar* var. *subglabrum* Thwaites, *Zingiber cliffordiae* Andrews, *Zingiber luridum* Salisb., *Zingiber montanum* (J. König ex Retz.) Theilade, *Zingiber purpureum* Roscoe, *Zingiber purpureum* var. *palamauense* (Haines) K.K. Khanna, *Zingiber xanthorrhizon* Steud.) [3] is commonly known as “Banada” in Bangladesh, “Phlai” in Thailand, “Jangliadrak” in India, and “Bangle” in Malaysia. It is reported to be native to Southeast Asia and has been extensively planted in Thailand, Malaysia, and Indonesia [4]. The rhizomes of this plant are used in traditional medicines for the treatment of constipation, dyspepsia, gastritis, stomach bloating and stomach-ache. Various parts of *Z. montanum* are used in Thailand as daily diet [5], while the rhizome is used in the as vermifuge in Malaysia, and applied for abscesses, colic, diarrhea, fever and intestinal disorders. In Northeast India, the rhizome paste was reported to be used in the treatment of dyspepsia and stomach bloating [6,7].




Figure 1. Photographs of *Zingiber montanum* plant (a) and rhizomes (b), and chemical structure of zerumbone (ZER) (c).

Zerumbone (ZER) (Figure 1c), a sesquiterpenoid, is one of the major compounds in the essential oils and rhizomes of *Z. montanum* [4]. In recent years, it has received much attention among researchers as a potent antitumor and anti-inflammatory compound [8–15]. *Z. montanum* being extensively used in traditional medicine but very few investigations were found for their bioactive constituents and mechanism based pharmacological actions. Thus, the main aim of this review is to scientifically analyze the available scientific information about the chemical constituents and pharmacological activities of extracts and compounds isolated from *Zingiber montanum* along with the various activities of ZER.

2. Traditional Uses of *Zingiber montanum*

Zingiber montanum rhizomes are traditionally used for the treatment of asthma, cough, colic, constipation, dyspepsia, diarrhea, inflammation, sprains, stomach bloating and wounds [4,16–31]. It is also used as a tonic and appetizer. It is given along with black pepper in the treatment of cholera and also used as a vermifuge [32]. The rhizome is also used to prepare cleansing solution for skin diseases [33]. The rhizome oil is applied in the treatment of swelling [25]. Rhizomes are also used as anti-inflammatory, antifungal, and antibacterial agent [19,34].

3. Bioactive Compounds

Phytochemical investigation of rhizomes of *Z. montanum* revealed the presence of numerous bioactive chemical constituents such as alkaloids, saponins, tannins, flavonoids, terpenoids, phenolic compounds, phlobatannins, steroids, and glycosides [35,36]. The gas chromatography-mass spectrometry (GC-MS) analysis of essential-oil constituents of fresh rhizomes of *Z. montanum* reported the presence of various compounds such as α -thujene, α -pinene, β -myrcene, α -terpinene, *p*-cymene, β -phellandrene, γ -terpinene, sabinene, sabinene hydrate, terpinolene, terpinen-4-ol, terpinyl acetate, β -sesquiphellandrene, and 4-(3,4-dimethoxyphenyl)but-1,3-diene (DMPBD) which were identified on the basis of retention time and comparison with standard compounds [37]. In another study, GC-MS analysis of essential oils of *Z. montanum* revealed the presence of sixty four constituents in leaf oil and thirty two constituents in the rhizome oil [38]. The major active chemical constituents of the rhizome oil were sabinene (27–34%), γ -terpinene (6–8%), α -terpinene (4–5%), terpinen-4-ol (30–5%), DMPBD (12–19%), triquinacene 1,4-bis (methoxy) (26.5%), (*Z*)-ocimene (22.0%), and β -phellandrene (1.0–4.4%) [35,37–39]. Whereas, the major constituents in leaf oil were sabinene (15.0%), β -pinene (14.3%), caryophyllene oxide (13.9%) and caryophyllene (9.5%) [38]. Kantoyos and Paisooksantivatana analyzed the chemical constituents in the essential oils obtained from ten *Zingiber* species in Thailand including *Z. montanum*. Among the studied plant species, the oil obtained from *Z. montanum* rhizomes had highest yield ($0.89 \pm 0.14\%$, *v/w*) and also showed highest total curcuminoid content (2.633% *w/w*) and terpinen-4-ol content ($14.5 \pm 2.59\%$) [37]. Structures of some of the main compounds in essential oils are given in Figure 2.




Figure 2. Structures of major constituents of leaf and rhizome essential oils.

There are also various reports on the compounds isolated from the extracts including non-volatile compounds from the rhizomes. They include mainly phenylbutanoids (Figure 3), flavonoids (Figure 4), terpenes and many other compounds. A list of some of these compounds is provided in Table 1.




Figure 3. Structures of some major compounds isolated from the extracts of rhizomes of *Z. montanum*.




Figure 4. Structures of kaempferol derivatives isolated from the extracts of rhizomes of *Z. montanum*.

Table 1. List of compounds isolated from the rhizomes of *Z. montanum*.

Extraction Solvent	Compounds	References
Hexane extract	(<i>E</i>)-4-(3,4-dimethoxyphenyl)-but-3-en-1-ol (<i>E</i>)-4-(3,4-Dimethoxyphenyl)-but-3-en-1-yl acetate (<i>E</i>)-3-(3,4-Dimethoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]cyclohex-1-ene	[40]
Hexane extract	4-(3',4'-Dimethoxyphenyl)but-3-ene 4-(3',4'-Dimethoxyphenyl)but-1,3-diene 4-(2',4',5'-Trimethoxyphenyl)but-3-ene 4-(2',4',5'-Trimethoxyphenyl)but-1,3-diene (<i>E</i>)-4-(3',4'-Dimethoxy)but-3-en-1-yl palmitate (<i>E</i>)-4-(3',4'-Dimethoxyphenyl)but-3-en-1-yl palmitate 3,4-Dimethoxybenzaldehyde 2,4,5-trimethoxybenzaldehyde	[41]
Chloroform extract	<i>cis</i> -3-(2',4',5'-Trimethoxyphenyl)-4-[(<i>E</i>)-2''',4''',5'''-trimethoxystyryl]cyclohex-1-ene <i>cis</i> -3-(3',4'-Dimethoxyphenyl)-4-[(<i>E</i>)-3''',4'''-dimethoxystyryl]cyclohex-1-ene <i>cis</i> -3-(3',4'-Dimethoxyphenyl)-4-[(<i>E</i>)-2''',4''',5'''-trimethoxystyryl]cyclohex-1-ene <i>cis</i> -3-(2',4',5'-Trimethoxyphenyl)-4-[(<i>E</i>)-3''',4'''-dimethoxystyryl]cyclohex-1-ene (<i>E</i>)-4-(3',4'-Dimethoxyphenyl)but-3-en-1-ol (<i>E</i>)-4-(3',4'-Dimethoxyphenyl)but-3-en-1-yl acetate 8-(3',4'-Dimethoxyphenyl)-2-methoxynaphtho-1,4-quinone	[27,42]

Table 1. Cont.

Extraction Solvent	Compounds	References
Chloroform extract	<i>cis</i> -4[(<i>E</i>)-3,4-Dimethoxystyryl]-3-(2,4,5-trimethoxyphenyl)cyclohex-1-ene <i>trans</i> -3-(3,4-Dimethoxyphenyl)-4[(<i>E</i>)-3,4-dimethoxystyryl]-cyclohex-1-ene <i>trans</i> -3-(3,4-Dimethoxyphenyl)-4-[(<i>E</i>)-2,4,5-trimethoxystyryl] cyclohex-1-ene (<i>E</i>)-4-(3,4-Dimethoxyphenyl) but-3-en-1-yl palmitate (<i>E</i>)-1-(3,4-Dimethoxyphenyl) but-1-ene (<i>E</i>)-1-(3,4-Dimethoxyphenyl) butadiene 2-Methoxy-8(2,4,5-trimethoxyphenyl)-naphtho-1,4-quinone Curcumin Vanillic acid Vanillin Veratric acid Terpinen-4-ol	[42]
Toluene extract	Cassumunaquinone 1 Cassumunaquinone 2 Alflabene Cassumunene 2-(3,4-Dimethoxystyryl) ethanol	[43,44]
Methanol extract	(<i>E</i>)-1-(3,4-Dimethoxyphenyl)but-1-ene (<i>E</i>)-1-(3,4-Dimethoxyphenyl)butadiene Zerumbone	[45]
Acetone extract	Cassumunin A Cassumunin B Cassumunin C	[46]
Acetone extract	Cassumunarin A Cassumunarin B Cassumunarin C	[47]
Acetone extract	(±)- <i>trans</i> -3-(2,4,5-Trimethoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]-cyclohexene (±)- <i>cis</i> -1,2-Bis[(<i>E</i>)-3,4-dimethoxystyryl]-cyclobutane (±)- <i>cis</i> -3-(3,4-Dimethoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]-cyclohexene (±)- <i>trans</i> -3(3,4-Dimethoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]-cyclohexene	[48]
Acetone extract	(<i>E</i>)-4-(4-Hydroxy-3-methoxyphenyl)but-3-en-1-yl acetate (<i>E</i>)-4-(4-Hydroxy-3-methoxyphenyl)but-2-en-1-ol (<i>E</i>)-2-Hydroxy-4-(3,4-dimethoxyphenyl)but-3-en-1-ol (<i>E</i>)-2-Methoxy-4-(3,4-dimethoxyphenyl)but-3-en-1-ol (<i>E</i>)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (<i>E</i>)-4-(3,4-Dimethoxyphenyl)but-3-en-1-yl acetate (<i>E</i>)-3-Hydroxy-1-(3,4-dimethoxyphenyl)but-1-ene	[49]
Hexane extract	(<i>E</i>)-4-(3',4' Dimethoxyphenyl)but-3-enyl acetate <i>cis</i> -3-(3',4'-Dimethoxyphenyl)-4-[(<i>E</i>)-3''',4'''-dimethoxystyryl]cyclohex-1-ene <i>cis</i> -3-(3',4'-Dimethoxyphenyl)-4-[(<i>E</i>)-2''',4''',5'''-trimethoxystyryl]cyclohex-1-ene <i>cis</i> -3-(2',4',5'-Trimethoxyphenyl)-4-[(<i>E</i>)-2''',4''',5'''-trimethoxystyryl]cyclohex-1-ene (<i>E</i>)-4-(3'-4'-dime-thoxyphenyl)but-3-en-1-ol	[50]

Table 1. Cont.

Extraction Solvent	Compounds	References
Ethanol extract	(<i>E</i>)-4-(3',4'-dimethoxyphenyl)but-3-enyl acetate (<i>E</i>)-4-(3',4'-dimethoxyphenyl)but-1,3-diene	[51]
Methanol extract	Phlain I Phlain II Phlain III Phlain IV Phlain V Phlain VI 3,4-Dimethoxybenzaldehyde 2,4,5-Trimethoxybenzaldehyde (<i>E</i>)-1-(3,4-Dimethoxyphenyl)buta-1,3-diene (<i>E</i>)-1-(2,4,5-Trimethoxyphenyl)buta-1,3-diene (<i>E</i>)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (<i>E</i>)-4-(3,4-Dimethoxyphenyl)but-3-enyl acetate (<i>E</i>)-1-(3,4-Dimethoxyphenyl)but-1-ene (<i>E</i>)-1-(2,4,5-Trimethoxyphenyl)but-1-ene (±)- <i>cis</i> -3-(3,4-Dimethoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]cyclohex-1-ene (±)- <i>cis</i> -3-(2,4,5-Trimethoxyphenyl)-4-[(<i>E</i>)-2,4,5-trimethoxystyryl]cyclohex-1-ene Cassumunaquinone 1 Cassumunaquinone 2 (-)-β-Sesquiphellandrene Curcumin Vanillic acid β-Sitosterol	[52]
Methanol extract	Cassumunol A Cassumunol B Cassumunol C Cassumunol D Cassumunol E Cassumunol F Cassumunol G Cassumunol H	[53]
Methanol extract	(±)- <i>trans</i> -3-(4'-Hydroxy-3'-methoxyphenyl)-4-[(<i>E</i>)-3''',4'''-dimethoxystyryl]cyclohex-1-ene (±)- <i>trans</i> -3-(3,4-Dimethoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]cyclohex-1-ene 4-(3,4-Dimethoxyphenyl)but-1,3-diene 4-(2,4,5-Trimethoxyphenyl)but-1,3-diene	[54]
Chloroform extract	(<i>E</i>)-4-(3,4-Dimethoxy-phenyl)but-3-en-1- <i>O</i> -β-D-glucopyranoside (±)- <i>trans</i> -3-(3,4-Dimethoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]cyclohex-1-ene (±)- <i>trans</i> -3-(4-Hydroxy-3-methoxyphenyl)-4-[(<i>E</i>)-3,4-dimethoxystyryl]cyclohex-1-ene 4-(2,4,5-Trimethoxyphenyl)-but-1,3-diene, 4-(3,4-Dimethoxyphenyl)but-1,3-diene (<i>E</i>)-4-(3,4-Dimethoxyphenyl)but-3-en-1-ol (<i>E</i>)-4-(3,4-Dimethoxyphenyl)but-3-en-1-yl acetate	[55]

Table 1. Cont.

Extraction Solvent	Compounds	References
Hexane extract	Zerumbone Zerumbol Buddledone A Furanodienone Germacrone Borneol Camphor	[20]
Chloroform extract	(E)-8(17),12-labdadiene-15,16-dial Camphor	[20]
Methanol extract	Zerumbone Kaempferol 3-O-methyl ether Kaempferol 3-O- α -rhamnopyranoside Kaempferol 3-O- α -(4''-O-acetyl)rhamnopyranoside Kaempferol 3-O- α -(3''-O-acetyl)rhamnopyranoside Kaempferol 3-O- α -(3'',4''-di-O-acetyl)rhamnopyranoside	[4]

4. Pharmacological Activities of *Z. montanum* Extracts and Compounds

Various pharmacological activities such as antimicrobial, anti-inflammatory, antioxidant, antihistaminic, smooth muscle relaxant, insecticidal activities are reported for the essential oils, extracts and some isolated compounds of *Z. montanum*. Some of these activities are discussed in detail in following sections.

4.1. Anti-Inflammatory Activity

The hexane extract of *Z. montanum* showed remarkable inhibitory effect on carrageenan-induced rat paw edema, acetic acid-inducing writhing reaction in mice and yeast-triggered hyperthermia in rats [56]. Moreover, phenylbutanoids have been reported as active constituents for anti-inflammatory activities [45]. Sabinene and terpinene-4-ol from essential oil of *Z. montanum* significantly reduced nuclear factor-kappa B (NF- κ B) protein expression in human leukemic monocyte lymphoma cells and interleukin-6 (IL-6) secretion in lipopolysaccharide (LPS) stimulated mice macrophage (RAW264.7) [57]. Methyl t-butyl ether (MTBE) and methanol extracts of *Zingiber* were effective to inhibit LPS induced in vitro production of prostaglandin E₂ (PGE₂) and TNF- α in human promonocytic U937 cells [58]. The methanol extract and phenylbutanoids of *Z. montanum* rhizome showed inhibitory effects on the production of NO from LPS induced peritoneal macrophages from mouse [52]. Methanol extract and its fractions (petroleum ether, hexane and aqueous) of *Z. montanum* showed anti-inflammatory activity in carrageenan-induced edema in rats, and acetic acid-induced vascular permeability and writhing test in mice [45].

4.2. Antifungal Activity

Jantan et al. reported that the *Z. montanum* rhizome oil at a dose of 0.75 mg/disc showed significant fungicidal activity against five dermatophytes fungi (*Trichophyton mentagrophytes*, *T. rubrum*, *Microsporum canis*, *M. nanum* and *Epidermophyton floccosum*) and three filamentous fungi (*Aspergillus niger*, *A. fumigatus* and *Mucor* sp.) [59]. Another study reported that the essential oil of the rhizome showed antifungal activity against *Thanetophorus cucumeris* [60]. *Z. montanum* exhibited high activity against the yeasts namely *Saccharomyces cerevisiae*, *Cryptococcus neoformans*, *Candida albicans*, *C. tropicalis*, *C. glabrata* [59]. Tripathi et al. reported the essential oils of *Z. montanum* at 500 mg/L showed 100% growth inhibition of fruit fungus *Botrytis cinerea* [61].

4.3. Antioxidant Activity

Many studies have demonstrated the antioxidant properties of *Z. montanum*. Extract from *Z. montanum* exhibited potent antioxidant activity hydroxyl radical (OH) scavenging assay [62]. Anastasia et al. reported the antioxidant activities of different fractions of *Z. montanum* by using 1,1-diphenyl-2-picrylhydrazyl (DPPH), hydrogen peroxide (H₂O₂), β -carotene bleaching assays. Among different fractions, chloroform fraction showed highest antioxidant activities in DPPH radical scavenging assay, hexane fraction showed highest activity in H₂O₂ assays and ethyl acetate fraction in β -carotene bleaching assay [63]. Masuda et al. studied the antioxidant activity of cassumunins A, B and C isolated from *Z. montanum* rhizomes acetone extract using a thiocyanate method which demonstrated that all cassumunins at a dose of 2.7 μ M inhibited accumulation of linoleic acid hyperoxide [64]. Bua-in and Paisooksantivatana reported the antioxidant activity of the extracts obtained from the rhizomes of *Z. montanum* collected from various localities in Thailand [65].

4.4. Antibacterial Activity

Z. montanum essential oil showed potent antibacterial activity against a number of Gram-positive and Gram-negative bacteria. Compared to methanolic extract, chloroform extract showed significant antimicrobial activity against a wide range of pathogens [66]. The rhizomes of *Z. montanum* are reported to be rich in essential oil effective against a range of pathogenic bacteria including *Escherichia coli*, *Klebsiella pneumonia*, *Salmonella paratyphi*, *S. typhi* and *Shigella flexneri* [27]. *Z. montanum* oil showed potent antimicrobial activity against seventy-four microbial strains with most potent activity against bacteria as such *Bacillus subtilis*, *E. coli*, and *Salmonella typhi* evaluated by disc-diffusion broth dilution method [19]. Boonyanugomol et al. reported significant antimicrobial activity of the essential oil of *Z. montanum* against Gram-negative *Acinetobacter baumannii* strains by agar disc-diffusion tests [67]. Sesquiterpenes, monoterpenes and diterpenes from *Z. montanum* showed various degrees of antimicrobial action against *B. cereus*, *Staphylococcus aureus*, *E. coli*, and *Pseudomonas aeruginosa* [68].

4.5. Analgesic and Antipyretic Activity

Plai cream, a water in oil emulsion prepared from the essential oil of rhizomes of *Z. montanum*, was reported to reduce the delayed onset of muscle soreness in healthy volunteers [30,69]. Strong antipyretic action of *Z. montanum* hexane extract was observed in yeast induced hyperthermia rats and analgesic activity was observed on acetic acid-induced writhing response in mice [56]. In another study, strong analgesic activity was observed in hot plate method compared to the standard pentazocine in case of chloroform and dichloromethane extract of *Z. montanum* [70].

4.6. Antiulcer Activity

Al-Amin et al. evaluated the antiulcer activity of methanol extract of *Z. montanum* in mice and it showed 62.0% and 83.1% inhibition of stomach lesions induced by 1N hydrochloric acid (HCl) at doses of 200 mg/kg and 400 mg/kg, respectively. The major compound isolated from the extract i.e., zerumbone also showed potent antiulcer activity in ethanol and indomethacin induced gastric lesions in mice [16]. Another study reported that different concentration of rhizome extracts of *Z. montanum* showed significant antiulcer activity in comparison with control group in aspirin-induced rat model [71].

4.7. Anti-Allergic Activity

Ethanol and aqueous extracts of *Z. montanum* exhibited the most potent anti-allergic activity in antigen induced beta hexosaminidase release in RBL-2H3 cell lines [72]. Capsules prepared from *Z. montanum* inhibited wheal and flare responses (Type 1 allergic reaction) induced by the mite skin prick test in allergic rhinitis patients [73].

4.8. Cytotoxicity Activity

Zulkhairi et al. reported the cytotoxicity activity of different extracts and compounds from rhizomes in human T-acute lymphoblastic leukemia cancer cells (CEMss) and human cervical cancer cells (HeLa) [74]. Crude methanolic extract of *Z. montanum* rhizomes showed significant cytotoxic activity in NIH 3T3 fibroblast cell line [65].

4.9. Other Activities

Dulpinijthmma et al. reported that *Z. montanum* capsule had remarkable role in the treatment of asthma by reducing the bronchial hyperresponsiveness [75]. Crude ethanolic *Z. montanum* extracts showed potent inhibitory effect on phorbol 12-myristate 13-acetate (PMA) induced mucous producing gene (MUC2, MUC5AC) as well as its protein expression in epithelial cell via inhibition of extracellular signal-regulated kinase pathway [76]. Dichloromethane extract from the rhizome of *Z. montanum* showed significant mosquito larvicidal activity [77]. Kato et al. reported the neutrophilic activity of phenylbutanoid constituents [17]. Okonogi et al. reported that essential oil showed moderate butyrylcholinesterase inhibitory [78].

5. Biological Activities of Zerumbone (ZER)

Zerumbone was initially isolated in 1960 from *Z. zerumbet* [79] and structurally characterized in 1965 [80]. Other than *Z. zerumbet* [81–84], it has been reported as one of the main constituents from *Z. montanum* [4,16,20,85]. It is also reported from many other species such as *Z. aromaticum* [84], *Z. spectabile* [86]. Zerumbone is widely studied for its various pharmacological activities such as anticancer, anti-inflammatory, antioxidant, antimicrobial, anti-ulcer, hepatoprotective activities among others [8,87–90]. These activities are explained in detail in following sections.

5.1. Anticancer Activity

Cancer is one of the leading causes of death worldwide [91]. Various studies have evaluated the anticancer potential of zerumbone. It was assessed against HeLa cell line and interestingly it showed a selective inhibition of HeLa cells proliferation (IC_{50} of $14.2 \pm 0.5 \mu\text{mol/L}$) via enhancement of cellular uptake compared to the normal cell line L929 [92]. Moreover, Rosa and co-workers revealed the anticancer mechanism of ZER on three cell lines including HeLa, B16F10 and undifferentiated Caco-2 cell lines. It was shown that ZER altered the total lipid and fatty acid profile in cancer cells, inducing marked changes in the phospholipid/cholesterol ratio [93]. In addition, the anticancer activity was assessed on Jurkat cells, human T cell leukemia, and it was found that ZER-pendant derivatives showed antiproliferative effects (IC_{50} values as low as 1–10 μM for most derivatives) [94]. A recent study reported that ZER inhibited cell migration of human esophageal squamous cancer by suppressing Rac1 expression, which is achieved through promoting Rac1 ubiquitination and degradation [95]. Wide number of studies had reported the in vivo, in vitro and in silico anticancer activities of ZER. Herein, an in vivo study showed that ZER significantly controls the growth of tumor and metastasis in BALB/c female mice injected with 4T1 (6-thioguanine resistant cell line) to spontaneously produce highly metastatic tumor [96]. Sithara et al. reported the anticancer activity of ZER against colorectal cancer cells, where they showed that ZER activates caspase 3, caspase 8, and caspase 9. ZER resulted in cell cycle arrest at the G2/M phase [97]. Similarly, other study reported induction of apoptosis in hepatoma HepG2 cells by ZER [98]. Eid and co-workers attempted to explore the underlying mechanism of ZER against breast cancer using in silico study. Since estrogen mediates several pathophysiological signaling pathways associated with cancer progression, the author had selected estrogen as a target for breast cancer and found that the promising molecular interaction, binding interaction, and stability of ZER and estrogen receptor- β (ER β) suggests ZER as lead compound for breast cancer [99]. More details of these activities are given in Table 2.

Table 2. Anticancer activities of zerumbone (ZER).

Experimental Models	Results and Possible Mechanisms	Reference
HeLa cells	ZER selectively inhibited the proliferation of HeLa cells and also enhanced the anti-proliferative activity of anticancer agents vinblastine and paclitaxel.	[92]
HeLa cells	ZER stimulated the apoptosis.	[100]
Non-small cell lung cancer (NSCLC) A549 cells	ZER showed suppression of OPN induced cell invasion through inhibition of FAK/AKT/ROCK pathway.	[101]
NSCLC cells	ZER induced mitochondrial apoptosis and enhanced the susceptibility to cisplatin.	[102]
DU145 prostate cancer cells	ZER exerted anticancer effects against hormone refractory DU145 prostate cancer cells mediated through the inhibition of aberrant signaling axis of IL-6/JAK2/STAT3.	[103]
Triple negative breast cancer (TNBC) cells	ZER suppressed IL-1 β induced cell invasion.	[104]
HCT-116 and SW48 cells	ZER exerted antimetastatic effects through inhibition of FAK/PI3k/NF- κ B-uPA signaling pathway.	[105]
P-338D1 and HL-60 cells and Splenocytes from CDF1 mice	ZER inhibited the growth of P-338D1 and HL-60 cells and prolonged the life of P-338D1-bearing CDF1 mice.	[106]
PANC-1 cells	ZER induced apoptosis through p53 signal pathway.	[107]
Breast cancer (MCF-7) cells	Cytotoxicity of ZER against estrogen receptor positive breast cancer (MCF-7) cells was significantly increased through co administration with TP5-iRGD peptide.	[108]
CEM-ss cells	ZER showed apoptotic activity on T-acute lymphoblastic leukemia.	[109]
PC-3 and DU-145, two human hormonerefractory prostate cancer (HRPC) cell lines	ZER inhibited tubulin assembly and induced a crosstalk between ER stress and mitochondrial insult, leading to apoptosis and autophagy in HRPCs.	[110]
HCT-116 and SW-48 cells	ZER reduces the risk of CRC progression by suppressing the β -catenin pathway via miR-200.	[111]
Jurkat cells	ZER conjugated with salicylic acid and benzoic acid derivatives inhibited the growth of human T-cell lymphoid Jurkat cells.	[94]
Esophageal squamous cell carcinomas (ESCC)	ZER inhibited cell migration of human esophageal squamous cancer by suppressing Rac1 expression through promoting Rac1 ubiquitination and degradation.	[95]
EC-109 cells	ZER inhibited the proliferation and induced apoptosis of esophageal cancer EC-109 cells by upregulating the mRNA expression of P53 and downregulating the mRNA expression of Bcl-2.	[112]
Canine mammary gland tumor (CMT) adenocarcinoma primary cell line.	ZER loaded into nanostructured lipid carrier (NLC) exerted CMT cell death via regulation of Bcl-2 and Bax gene expressions and caspase activation.	[9]
Colorectal cancer cells (SW480)	ZER activated caspase 3, caspase 8, and caspase 9 and resulted in cell cycle arrest at the G2/M phase	[97]
Human colonic adenocarcinoma cell lines (LS174T, LS180, COLO205, and COLO320DM)	ZER inhibited the proliferation of LS174T, LS180, COLO205, and COLO320DM cell lines.	[113]
SKBR3 breast cancer cells	ZER suppressed EGF-induced phosphorylation of STAT3.	[114]
HCC1806 cells	ZER suppressed TGF- β 1-induced FN, MMP-2, and MMP-9 expression.	[115]
HepG2 cells	ZER induced apoptosis in hepatoma HepG2 cells.	[98]
HepG2 cells	ZER inhibited the proliferation, and invasion and migration of hepatoma cells.	[116]
Laryngeal carcinoma cells (Hep-2)	ZER arrested Hep-2 proliferation at S and G2/M phases and induced cell death.	[117]

Table 2. Cont.

Experimental Models	Results and Possible Mechanisms	Reference
BALB/c female mice	ZER controled the growth of tumor and metastasis via delayed progression of cancer cell cycle and apoptosis.	[96]
Male ICR mice	ZER effectively suppressed mouse colon and lung carcinogenesis through multiple modulatory mechanisms of growth, apoptosis, inflammation and expression of NFκB and HO-1.	[118]
Female Balb/c mice	ZER induced apoptosis in cervical tissues from female Balb/c mice treated prenatally with diethylstilboestrol.	[119]
Caov-3 and HeLa cells	ZER inhibited cancer cell growth through the induction of apoptosis and arrested cell cycle at G2/M phase.	[120]
Female BALB/c Mice	Combination of ZER and cisplatin modulated the serum level of interleukin 6 in mice with cervical intraepithelial neoplasia.	[121]
HeLa cells	ZER caused prominent growth retardation of HeLa cells.	[122,123]
HepG2 cells	ZER increased apoptosis in HepG2 cells by up-regulating pro-apoptotic Bax protein and suppressing anti-apoptotic Bcl-2 protein expression.	[124]
MCF-7 and MDAMB-231cells	ZER inhibited the viability of MCF-7 and MDA-MB-231 cells	[125]
HepG2 cells	Highly soluble inclusion complex of ZER-hydroxypropyl-β-cyclodextrin induced apoptosis of HepG2 via Caspase8/BH3 interacting-domain death agonist cleavage switch and modulating Bcl2/Bax ratio.	[12]
HepG2, human umbilical vein endothelial cells (HUVECs)	ZER inhibited proliferation and migration of HepG2 cells and inhibited angiogenesis, and expression of matrix metalloproteinase-9, vascular endothelial growth factor (VEGF) and VEGF receptor proteins in HUVECs cell line.	[126]
MDA-MB-231, MCF-7, and MCF-10A cells	ZER induced G2/M phase cell cycle arrest and Bax/Bak mediated apoptosis in human breast cancer cells, and also retarded the growth of MDA-MB-231 xenografts in vivo.	[127]
MCF-7 and MDA-MB-231 cells	ZER treatment resulted in increased Notch2 cleavage accompanied by Persenlin-1 protein expression.	[88]
Human PaCa cell lines BxPC-3 and MIA PaCa-2	ZER blocked the PaCa-associated angiogenesis through the inhibition of NF-κB and NF-κB dependent proangiogenic gene products.	[128]
Human renal cell carcinoma (RCC) cell line 786-O and Caki-1	ZER acted as a novel blocker of STAT3 signaling cascade.	[129]
Oral squamous cell carcinoma (OSCC) lines	ZER inhibited the activation of CXCR4-RhoA and PI3K-mTOR signaling pathways resulting into reduced cell viability of OSCC cells.	[130]
Mouse epidermal cell line, JB6 Cl41	ZER induced HO-1 expression mediated through activation of Nrf2 signaling.	[89]
MDA-MB-231, MDA-MB-468, MDA-MB-361, T-47D, MCF-7 and MCF-10A cells	ZER inhibited the growth of breast cancer call line by downregulating CD1d overexpression.	[131]
Murine leukemia induced with WEHI-3B cells	ZER-loaded nanostructured lipid carrier (ZER-NLC) induced mitochondrial-dependent apoptotic pathway in murine leukemia.	[132]
Human gastric cancer cell line SGC-7901	ZER induced human gastric cancer cells apoptosis.	[133]
Human malignant melanoma (MM) A375 cell line	ZER induced apoptosis of A375 cells by activating Caspase-3.	[15]
Human Rac1 were cloned from HEK293 T cells	ZER inhibits cell migration by suppressing Rac1 expression.	[95]

Table 2. Cont.

Experimental Models	Results and Possible Mechanisms	Reference
Huh-7 and MHCC-LM3 cells and NSG mice	ZER prevented liver tumorigenesis through regulating cell metabolism and inducing cell cycle arrest and apoptosis.	[134]
Human glioblastoma multiforme (GBM8401) cells	ZER induced apoptosis through inactivation of IKK α , followed by Akt and FOXO1 phosphorylation and caspase-3 activation.	[135]
Human skin melanoma cell line CHL-1	ZER showed chemotherapeutic effects on human melanoma cells by altering mitochondrial function.	[136]
K562 cells	ZER treatment in K562 cells induced apoptosis through mitochondrial mediated pathway linked to upregulation of total histone H2AX, increased calcium and ROS production.	[137]

FAK: focal adhesion kinase, AKT: protein kinase B, ROCK: Rho-associated protein kinase, OPN, IL-6: interleukin-6, JAK2: Janus kinases 2, STAT3: signal transducer and activator of transcription proteins 3, IL-1 β : interleukin-1 β , PI3k: phosphatidylinositol-3-kinase, NF- κ B: nuclear factor kappa B, uPA: urokinase plasminogen activator, MMP: matrix metalloproteinase, ER: endoplasmic reticulum, Rac1: Ras-related C3 botulinum toxin substrate, mRNA: messenger ribonucleic acid, Bcl-2: B-cell lymphoma 2, TGF- β 1: transforming growth factor beta 1, Bax: Bcl-2-associated X protein, Hsp90/Cdc37: heat shock protein 90 co-chaperone Cdc37, RhoA: Ras homolog family member A, mTOR: mechanistic target of rapamycin, HO-1: heme oxygenase -1, Nrf2: nuclear factor-erythroid factor 2-related factor 2, IKK α inhibitory- κ B kinase- α , FOXO1: forkhead box protein O1, H2AX: H2A histone family member X.

5.2. Anti-Inflammatory Activity

The anti-inflammatory property of ZER is also reported by many studies in vitro and in vivo studies using different models. Various cellular mechanisms of anti-inflammatory activities are also reported. The details of these activities are given in Table 3.

Table 3. Anti-inflammatory activity of ZER.

In Vitro/In Vivo	Models	Activity	References
In vitro	Macrophages differentiated from human monocyte (THP-1)	ZER inhibited the secretion of pro-inflammatory cytokines in lipopolysaccharide (LPS)-activated inflammation in THP-1 cell-derived macrophages.	[138]
In vivo	Mice (endotoxin-treated mice induce acute lung injury)	ZER reduced leukocytes infiltration into the alveolar space and inhibited lung edema in LPS-induced acute lung injury.	[139]
In vivo	Rats using Paw edema model	ZER reduced both λ -carrageenan- and prostaglandin E ₂ -induced inflammation.	[140]
In vitro	RAW264.7 murine macrophages	ZER induced proteo-stress leading to activation of HSF1 resulting into anti-inflammatory activity.	[141]
In vivo	Wild-type C57BL/6 mice	ZER decreased ETBF-induced colitis through inhibition of NF- κ B signaling pathway.	[142]
In vitro	U937 monocytes	ZER suppressed the activation of inflammatory markers in the macrophages via MyD88-dependent NF- κ B/MAPK/PI3K-Akt signaling pathways.	[143]
In vivo	Adult male pathogen-free ICR mice	ZER showed protective effect on acute lung injury induced by LPS via suppression of intracellular adhesion molecules-1, IL-1 β , macrophage inflammatory protein -2, downregulation of Akt, p38 MAPK/JNK, and I κ B/NF- κ B pathways.	[144]
In vivo	Adult male pathogen-free ICR mice	ZER showed protective effect on acute lung injury induced by LPS- via upregulation of antioxidative enzymes and Nrf2/HO-1 pathway.	[145]
In vitro	RAW 264.7 cells	ZER inhibited proinflammatory gene inducible nitric oxide (iNOS) and COX2 expression by attenuating I κ B degradation.	[146]
In vitro	RAW264.7 cells	ZER significantly accelerated spontaneous COX-2 mRNA decay.	[147]
In vitro	Murine macrophage RAW264.7 cells	ZER stimulated HO-1.	[148]

5.3. Antimicrobial Activity

Various studies have reported the potent antibacterial activity of zerumbone [87,149]. A recent study reported the inhibitory effect of ZER extract and its compounds against multi-drug resistant and methicillin resistant *Staphylococcus aureus* [20]. In addition, ZER has an anti-biofilm potential; where it is reported to significantly suppress the expression level of BmeB12 along with antibacterial activity against *Bacteroides fragilis* [150]. Moreover, a study reported the bactericidal action of ZER against the carcinogenic bacterium *Streptococcus mutans* (ATCC35668) [151]. Synthetic derivatives of zerumbone are also reported as potent antimicrobial compounds [152].

5.4. Other Pharmacological Activities

Various other pharmacological activities are also reported for ZER such as immunomodulatory activity, neuroprotective effect, antinociceptive, anti-platelet and anti-melanogenic activities (Table 4). Different studies reported the immunomodulatory properties of ZER. Keong et al. revealed ZER activates mice thymocytes, splenocytes and peripheral blood mononuclear cells (PBMC) at dose dependent pattern [153]. A similar study assessed a commercially obtained ZER on human peripheral blood, where it showed that ZER activates human lymphocytes and upregulates interleukin-12p70 cytokine [154]. For neuroprotective effect of ZER, Hamdi et al. reported that ZER oxide protects NG108-15 cells from H₂O₂ induced oxidative stress [155]. Apart from that, ZER has a gastroprotective effect, where ZER reduces submucosal edema and leukocyte infiltration. On the other hand, a recent in vivo study reported the antinociceptive activity of ZER on mouse, where ZER suppresses inflammatory mediators without any signs of sedation [156]. An in vivo assessment reported the anti-platelet action of ZER investigated from human blood [157]. For the anti-melanogenic activity, a recent study reported that ZER attenuates melanin accumulation in α -melanoma cells [158].

Table 4. Other pharmacological activities of ZER.

In Vitro/In Vivo	Model Cells/Animals	Activity	References
Hepatoprotective activity			
In vitro	C57BL/6 mice	In a chronic liver injury model induced by CCl ₄ , ZER treatment alleviated the hepatocellular toxicity and inhibited activation of primary hepatic stellate cells. ZER restored the activities of antioxidant enzymes such as superoxide dismutase and glutathione peroxidase. It also reduces the release of pro-inflammatory cytokines such as IL-6 and TNF- α , and inactivated the TLR4/NF- κ B/COX-2 pathway in acute liver injury induced by CCl ₄ in mice.	[159]
In vivo	Mice	ZER possessed protective activity against paracetamol-induced acute hepatotoxicity.	[160]
In vivo	Rats		[161]
Immunosuppressive and Immunomodulatory activities			
In vivo	Male wistar rats	ZER inhibited the migration of neutrophils, expressions of CD11b/CD18 integrin, phagocytic activity, and production of reactive oxygen species	[162]
In vitro	CD18 integrin expression and phagocytic engulfment	ZER showed strong inhibition on the phagocytosis of neutrophils. ZER reduced ovalbumin (OVA)-specific immunoglobulin E (IgE) and induced IgG2a antibody production. It also reduced the production of eotaxin, keratinocyte-derived chemokine (KC), IL-4, IL-5, IL-10, and IL-13, and promoted Th1 cytokine interferon (IFN)- γ production.	[163]
In vitro	Asthmatic mouse model		[164]
In vitro	Zymogen and PMA based chemiluminescence assay	ZER significantly inhibited intracellular and extracellular reactive oxygen species (ROS) production.	[165]

Table 4. Cont.

In Vitro/In Vivo	Model Cells/Animals	Activity	References
Anti-hypercholesterolemic activity			
In vivo	Rabbit	ZER prevented the development of atherosclerotic lesions and suppressed macrophage aggregation.	[166]
Anti-hyperlipidemic activity			
In vivo	high-fat diet (HFD)-induced hyperlipidemic hamsters	ZER improved dyslipidemia by modulating lipolytic and lipogenic pathways of lipids metabolism	[167]
Anti-obesity activity			
In vivo	C57BL/6N mice	ZER ameliorated diet-induced obesity and inhibited adipogenesis by restoring AMPK-regulated lipogenesis and the microRNA-146b/SIRT1-mediated adipogenesis.	[168]
In vivo	C57BL/6 mice	ZER decreased the levels of plasma triglycerides well as plasma insulin and leptin.	[169]
Anti-hyperglycemia and related activities			
In vitro	MDCK cells	ZER increased AMPK phosphorylation at Thr172 under normal/high glucose without affecting mitochondrial function.	[170]
In vivo	STZ-diabetic rats	ZER ameliorated diabetic nephropathy by inhibiting hyperglycemia-induced inflammation.	[171]
In vivo	STZ-diabetic rats	ZER protected from hyperglycemia-induced retinal damage.	[172]
In vitro	INS-1 rat pancreatic β cells	ZER protected against high glucose-induced apoptosis of INS-1 pancreatic β cells.	[173]
Wound healing activity			
In vivo		ZER treated wound sections showed greater tissue regeneration and more fibroblasts possibly through the enhanced expression of VEGF, TGF- β 1 and collagen IV.	[174]
Antiallergic activity			
In vivo	Female BALB/c and C57BL/6 mice	ZER showed antiallergic effect via modulation of Th1/Th2 cytokines in an asthmatic mouse model	[164]

Although zerumbone shows promising biological activities, its low water solubility and poor bioavailability are the limiting factors for wider applications of various formulations containing zerumbone. Few studies have been reported aimed at improving the solubility and bioavailability of zerumbone such as formulation inclusion complexes with cyclodextrin [8,175], nanostructured lipid carriers [9], etc.

6. Conclusions and Future Prospects

This review highlighted the traditional food and medicinal uses, bioactive chemical constituents, and pharmacological activities of *Z. montanum*. Various bioactive compounds have been isolated and identified from the different plant parts. The most widely used and studied part was rhizome. Studies have reported both volatile and non-volatile compounds from the rhizomes. Sesquiterpene lactone, ZER was one of the main components in the rhizomes. ZER has been studied widely for its anticancer, anti-inflammatory, and other pharmacological activities. Future studies should focus on the exploration of various pharmacological activities of other compounds including flavonoids and phenylbutanoids. Bioassay guided isolation may result in the isolation of other active components from the extracts. Future studies should also focus on in vivo studies dealing with pharmacological and pharmacokinetic evaluations. Moreover, clinical studies should be conducted to validate the promising biological activities of ZER. Based on these data, *Z. montanum* can be a potential source for the development of functional and health beneficial food products.

Author Contributions: Conceptualization, H.P.D.; investigation, H.P.D., K.R.P., M.M.H.; writing—original draft preparation, H.P.D., K.R.P., M.M.H., A.A.-D., A.I.D., J.E., R.L., N.D.; writing—review and editing, H.P.D., K.R.P., N.K.J., S.K.S., P.M.H., Y.C., D.K.C., K.D. All authors have read and agreed to the published version of the manuscript.

Funding: Philip M. Hansbro (PMH) is funded by a Fellowship and grants from the National Health and Medical Research Council (NHMRC) of Australia (1175134) and by UTS.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sharifi-Rad, M.; Varoni, E.M.; Salehi, B.; Sharifi-Rad, J.; Matthews, K.R.; Ayatollahi, S.A.; Kobarfard, F.; Ibrahim, S.A.; Mnayer, D.; Zakaria, Z.A.; et al. Plants of the genus *Zingiber* as a source of bioactive phytochemicals: From tradition to pharmacy. *Molecules* **2017**, *22*, 2145. [[CrossRef](#)]
2. Sabulal, B.; Dan, M.; Kurup, R.; Pradeep, N.S.; Valsamma, R.K.; George, V. Caryophyllene-rich rhizome oil of *Zingiber nimmonii* from South India: Chemical characterization and antimicrobial activity. *Phytochemistry* **2006**, *67*, 2469–2473. [[CrossRef](#)]
3. World Flora Online (WFO) (2021): *Zingiber montanum* (J.Koenig) Link ex A.Dietr. Available online: <http://www.worldfloraonline.org/taxon/wfo-0000617206> (accessed on 22 October 2021).
4. Hassan, M.M.; Adhikari-Devkota, A.; Imai, T.; Devkota, H.P. Zerumbone and Kaempferol Derivatives from the Rhizomes of *Zingiber montanum* (J. Koenig) Link ex A. Dietr. from Bangladesh. *Separations* **2019**, *6*, 31. [[CrossRef](#)]
5. Lim, T.K. *Zingiber montanum*. In *Edible Medicinal and Non-Medicinal Plants*; Springer: Cham, Switzerland, 2016; Volume 12.
6. Wolff, X.Y.; Astuti, I.P.; Brink, M. *Zingiber* GR Boehmer. In *Plant Resources of South-East Asia 13: Spices*; Backhuys Publishers: Kerckwerpe, The Netherlands, 1999; pp. 233–238.
7. Anasamy, T.; Abdul, A.B.; Sukari, M.A.; Abdelwahab, S.I.; Mohan, S.; Kamalidehghan, B.; Azid, M.Z.; Muhammad Nadzri, N.; Andas, A.; Kuan Beng, N. A phenylbutenoid dimer, cis-3-(3',4'-dimethoxyphenyl)-4-[(E)-3''',4'''-dimethoxystyryl] cyclohex-1-ene, exhibits apoptogenic properties in T-acute lymphoblastic leukemia cells via induction of p53-independent mitochondrial signalling pathway. *Evid. Based Complement. Altern. Med.* **2013**, *2013*, 939810. [[CrossRef](#)] [[PubMed](#)]
8. Hassan, M.M.; Mohammed, A.F.A.; Elamin, K.M.; Devkota, H.P.; Ohno, Y.; Motoyama, K.; Higashi, T.; Imai, T. Improvement of pharmaceutical properties of zerumbone, a multifunctional compound, using cyclodextrin derivatives. *Chem. Pharm. Bull.* **2020**, *68*, 1117–1120. [[CrossRef](#)] [[PubMed](#)]
9. Foong, J.N.; Selvarajah, G.T.; Rasedee, A.; Rahman, H.S.; How, C.W.; Beh, C.Y.; Teo, G.Y.; Ku, C.L. Zerumbone-loaded nanostructured lipid carrier induces apoptosis of canine mammary adenocarcinoma cells. *Biomed. Res. Int.* **2018**, *2018*, 8691569. [[CrossRef](#)]
10. Park, J.-H.; Park, G.M.; Kim, J.-K. Zerumbone, sesquiterpene photochemical from ginger, inhibits angiogenesis. *Korean J. Physiol. Pharmacol.* **2015**, *19*, 335–340. [[CrossRef](#)]
11. Rahman, H.S.; Rasedee, A.; Abdul, A.B.; Zeenathul, N.A.; Othman, H.H.; Yeap, S.K.; How, C.W.; Hafiza, W.A.G.W.N. Zerumbone-loaded nanostructured lipid carrier induces G2/M cell cycle arrest and apoptosis via mitochondrial pathway in a human lymphoblastic leukemia cell line. *Int. J. Nanomed.* **2014**, *9*, 527.
12. Muhammad Nadzri, N.; Abdul, A.B.; Sukari, M.A.; Abdelwahab, S.I.; Eid, E.E.M.; Mohan, S.; Kamalidehghan, B.; Anasamy, T.; Ng, K.B.; Syam, S.; et al. Inclusion complex of zerumbone with hydroxypropyl- β -Cyclodextrin induces apoptosis in liver hepatocellular HepG2 Cells via caspase 8/BID cleavage switch and modulating Bcl2/Bax ratio. *Evid. Based Complement. Altern. Med.* **2013**, *2013*, 810632. [[CrossRef](#)]
13. Sulaiman, M.R.; Perimal, E.K.; Akhtar, M.N.; Mohamad, A.S.; Khalid, M.H.; Tasrip, N.A.; Mokhtar, F.; Zakaria, Z.A.; Lajis, N.H.; Israf, D.A. Anti-inflammatory effect of zerumbone on acute and chronic inflammation models in mice. *Fitoterapia* **2010**, *81*, 855–858. [[CrossRef](#)]
14. Girisa, S.; Shabnam, B.; Monisha, J.; Fan, L.; Halim, C.E.; Arfuso, F.; Ahn, K.S.; Sethi, G.; Kunnumakkara, A.B. Potential of Zerumbone as an Anti-Cancer Agent. *Molecules* **2019**, *24*, 734. [[CrossRef](#)] [[PubMed](#)]
15. Wang, S.D.; Wang, Z.H.; Yan, H.Q.; Ren, M.Y.; Gao, S.Q.; Zhang, G.Q. Chemotherapeutic effect of Zerumbone on melanoma cells through mitochondria-mediated pathways. *Clin. Exp. Dermatol.* **2016**, *41*, 858–863. [[CrossRef](#)] [[PubMed](#)]
16. Al-Amin, M.; Sultana, G.N.N.; Hossain, C.F. Antiulcer principle from *Zingiber montanum*. *J. Ethnopharmacol.* **2012**, *141*, 57–60. [[CrossRef](#)] [[PubMed](#)]
17. Kato, E.; Kubo, M.; Okamoto, Y.; Matsunaga, Y.; Kyo, H.; Suzuki, N.; Uebaba, K.; Fukuyama, Y. Safety Assessment of Bangle (*Zingiber purpureum* Rosc.) Rhizome Extract: Acute and Chronic Studies in Rats and Clinical Studies in Human. *ACS Omega* **2018**, *3*, 15879–15889. [[CrossRef](#)] [[PubMed](#)]

18. Singh, H.; Lily, M.K.; Dangwal, K. Evaluation and comparison of polyphenols and bioactivities of wild edible fruits of North-West Himalaya, India. *Asian Pac. J. Trop. Dis.* **2015**, *5*, 888–893. [[CrossRef](#)]
19. Pithayanukul, P.; Tubprasert, J.; Wuthi-Udomlert, M. In vitro antimicrobial activity of *Zingiber cassumunar* (Plai) oil and a 5% Plai oil gel. *Phyther. Res. Int. J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv.* **2007**, *21*, 164–169.
20. Siddique, H.; Pendry, B.; Rahman, M.M. Terpenes from *Zingiber montanum* and their screening against multi-drug resistant and methicillin resistant *Staphylococcus aureus*. *Molecules* **2019**, *24*, 385. [[CrossRef](#)]
21. Kasahara, S.; Henmi, S. Medicine Herb Index in Indonesia. *Eisai Indones.* **1986**, *92*, 92.
22. Elliott, S.; Brimacombe, J. The medicinal plants of Gunung Leuser National Park, Indonesia. *J. Ethnopharmacol.* **1987**, *19*, 285–317. [[CrossRef](#)]
23. Hsu, H.-Y.; Chen, Y.-P.; Jyl, S. *Oriental Materia Medica: A Concise Guide*; Oriental Healing Arts Institute: Los Angeles, CA, USA, 1986.
24. Dymock, W. *Pharmacographia Indica*; Kegan Paul, Trench, Trubner & Co.: London, UK, 1983; Volume 3.
25. Nayar, M.P.; Ramamurthy, K.; Agarwal, V.S. *Economic Plants of India*; Kailash Prakashan: Delhi, India, 1989.
26. Tham, T.C.; Ng, M.X.; Gan, S.H.; Chua, L.S.; Aziz, R.; Abdullah, L.C.; Ong, S.P.; Chin, N.L.; Law, C.L. Impacts of different drying strategies on drying characteristics, the retention of bio-active ingredient and colour changes of dried Roselle. *Chin. J. Chem. Eng.* **2018**, *26*, 303–316. [[CrossRef](#)]
27. Amatayakul, T.; Cannon, J.R.; Dampawan, P.; Dechatiwongse, T.; Giles, R.G.F.; Huntrakul, C.; Kusamran, K.; Mokkaasmit, M.; Rastton, C.L.; Reutrakul, V.; et al. Chemistry and crystal structures of some constituents of *Zingiber cassumunar*. *Aust. J. Chem.* **1979**, *32*, 71–88. [[CrossRef](#)]
28. Cheechareoan, S.; Pathanawiriyasirikul, T.; Manmee, C.; Janpol, K. Efficacy of Plai cream in adult patients with muscle strain: A randomized, double-blind, placebo-controlled trial. *J. Med. Assoc. Thai.* **2016**, *99*, S147–S152.
29. Chienthavorn, O.; Poonsukcharoen, T.; Pathrakorn, T. *Pressurized Liquid and Superheated Water Extraction of Active Constituents from Zingiber Cassumunar Roxb. Rhizome*; Kasetsart University: Bangkok, Thailand, 2011; Volume 46, ISBN 9742747431.
30. Manimmanakorn, N.; Manimmanakorn, A.; Boobphachart, D.; Thuwakum, W.; Laupattarakasem, W.; Hamlin, M.J. Effects of *Zingiber cassumunar* (Plai cream) in the treatment of delayed onset muscle soreness. *J. Integr. Med.* **2016**, *14*, 114–120. [[CrossRef](#)]
31. Sirochana, S. Efficacy of Plai Cream Compared with Diclofenac Gel in Osteoarthritis of Knee. *Maharakham Hosp. J.* **2010**, *7*, 53–60.
32. Jain, S.K.; Tarafder, C.R. Medicinal plant-lore of the santals. *Econ. Bot.* **1970**, *24*, 241–278. [[CrossRef](#)]
33. Oliveros, M.B. Preformulation studies on terpinen-4-ol from *Zingiber purpureum* Rosc. In *Proceedings of the 2nd Symposium on the Family Zingiberaceae*; Wu, T.L., Wu, Q.G., Chen, Z.Y., Eds.; Zhongshan University Press: Guangzhou, China, 1996; pp. 180–186.
34. Chaiwongsa, R.; Ongchai, S.; Boonsing, P.; Kongtawelert, P.; Panthong, A.; Reutrakul, V. Active compound of *Zingiber cassumunar* Roxb. down-regulates the expression of genes involved in joint erosion in a human synovial fibroblast cell line. *Afr. J. Tradit. Complement. Altern. Med.* **2012**, *10*, 40–48. [[CrossRef](#)] [[PubMed](#)]
35. Joram, A.; Das, A.K.; Mahanta, D. Evaluation of antioxidant and phenolic contents of *Zingiber montanum* (J.Koenig) Link ex Dietr.: A potential ethnomedicinal plant of Arunachal Pradesh, India. *Pleione* **2018**, *12*, 255. [[CrossRef](#)]
36. Majaw, S.; Moirangthem, J. Qualitative and Quantitative Analysis of *Clerodendron colebrookianum* Walp. Leaves and *Zingiber cassumunar* Roxb. Rhizomes. *Ethnobot. Leaflet.* **2009**, *2009*, 3.
37. Kantayos, V.; Paisooksantivatana, Y. Antioxidant Activity and selected chemical components of 10 *Zinger* spp. in Thailand. *J. Dev. Sustain. Agric.* **2012**, *7*, 89–96.
38. Bhuiyan, M.N.I.; Chowdhury, J.U.; Begum, J. Volatile constituents of essential oils isolated from leaf and rhizome of *Zingiber cassumunar* Roxb. *Bangladesh J. Pharmacol.* **2008**, *3*, 69–73. [[CrossRef](#)]
39. Verma, R.S.; Joshi, N.; Padalia, R.C.; Singh, V.R.; Goswami, P.; Verma, S.K.; Iqbal, H.; Chanda, D.; Verma, R.K.; Darokar, M.P.; et al. Chemical composition and antibacterial, antifungal, allelopathic and acetylcholinesterase inhibitory activities of cassumunar-ginger. *J. Sci. Food Agric.* **2018**, *98*, 321–327. [[CrossRef](#)]
40. Taechowisan, T.; Suttichokthanakorn, S.; Phutdhawong, W.S. Antibacterial and cytotoxicity activities of phenylbutanoids from *Zingiber cassumunar* Roxb. *J. Appl. Pharm. Sci.* **2018**, *8*, 121–127.
41. Tuntiwachwuttikul, P.; Pancharoen, O.; Jaipetch, T.; Reutrakul, V. Phenylbutanoids from *Zingiber cassumunar*. *Phytochemistry* **1981**, *20*, 1164–1165. [[CrossRef](#)]
42. Kuroyanagi, M.; Fukushima, S.; Yoshihira, K.; Natori, S.; Dechatiwongse, T.; Mihashi, K.; Nishi, M.; Hara, S. Further Characterization of the Constituents of a Thai Medicinal Plant, *Zingiber cassumunar* ROXB. *Chem. Pharm. Bull.* **1980**, *28*, 2948–2959. [[CrossRef](#)]
43. Dinter, H.; Hänsel, R.; Pelter, A. The Structures of Cassum unaquinones 1 and 2 from *Zingiber cassumunar*. *Z. Für Naturforsch. C* **1980**, *35*, 154–155. [[CrossRef](#)]
44. Dinter, H.; Hänsel, R.; Pelter, A. Isolation of Two Phenylbutadiene Dimers and One Monomeric 4-Phenylbut-3-ene from *Zingiber cassumunar* (roxb.). *Z. Für Naturforsch. C* **1980**, *35*, 156–158. [[CrossRef](#)]
45. Ozaki, Y.; Kawahara, N.; Harada, M. Anti-inflammatory Effect of *Zingiber cassumunar* ROXB. and Its Active Principles. *Chem. Pharm. Bull.* **2011**, *39*, 2353–2356. [[CrossRef](#)] [[PubMed](#)]
46. Masuda, T.; Jitoe, A.; Nakatani, N. Structures of Cassumunin A, B, and C, New Potent Antioxidants from *Zingiber cassumunar*. *Chem. Lett.* **2006**, *22*, 189–192. [[CrossRef](#)]

47. Jitoe, A.; Masuda, T.; Mabry, T.J. Novel Antioxidants, Cassumunarin A, B, and C, from *Zingiber cassumunar*. *Tetrahedron Lett.* **1994**, *35*, 981–984. [[CrossRef](#)]
48. Jitoe, A.; Masuda, T.; Nakatani, N. Phenylbutenoid dimers from the rhizomes of *Zingiber cassumunar*. *Phytochemistry* **1993**, *32*, 357–363. [[CrossRef](#)]
49. Masuda, T.; Jitoe, A. Phenylbutenoid monomers from the rhizomes of *Zingiber cassumunar*. *Phytochemistry* **1995**, *39*, 459–461. [[CrossRef](#)]
50. Pongprayoon, U.; Soontornsaratune, P.; Jarikasem, S.; Sematong, T.; Wasuwat, S.; Claeson, P. Topical antiinflammatory activity of the major lipophilic constituents of the rhizome of *Zingiber cassumunar*. Part I: The essential oil. *Phytomedicine* **1997**, *3*, 319–322. [[CrossRef](#)]
51. Lu, Y.; Sun, C.; Wang, Y.; Pan, Y. Preparative isolation and purification of two phenylbutenoids from the rhizomes of *Zingiber cassumunar* by upright counter-current chromatography. *J. Chromatogr. A* **2005**, *1089*, 258–262. [[CrossRef](#)]
52. Nakamura, S.; Iwami, J.; Matsuda, H.; Wakayama, H.; Pongpiriyadacha, Y.; Yoshikawa, M. Structures of New Phenylbutanoids and Nitric Oxide Production Inhibitors from the Rhizomes of *Zingiber cassumunar*. *Chem. Pharm. Bull.* **2009**, *57*, 1267–1272. [[CrossRef](#)]
53. Matsuda, H.; Nakamura, S.; Iwami, J.; Li, X.; Pongpiriyadacha, Y.; Nakai, M.; Kubo, M.; Fukuyama, Y.; Yoshikawa, M. Invasion Inhibitors of Human Fibrosarcoma HT 1080 Cells from the Rhizomes of *Zingiber cassumunar*: Structures of Phenylbutanoids, Cassumunols. *Chem. Pharm. Bull.* **2011**, *59*, 365–370. [[CrossRef](#)]
54. Han, A.R.; Min, H.Y.; Windono, T.; Jeohn, G.H.; Jang, D.S.; Lee, S.K.; Seo, E.K. A new cytotoxic phenylbutenoid dimer from the rhizomes of *Zingiber cassumunar*. *Planta Med.* **2004**, *70*, 1095–1097. [[CrossRef](#)] [[PubMed](#)]
55. Han, A.R.; Kim, M.S.; Jeong, Y.H.; Lee, S.K.; Seo, E.K. Cyclooxygenase-2 inhibitory phenylbutenoids from the rhizomes of *Zingiber cassumunar*. *Chem. Pharm. Bull.* **2005**, *53*, 1466–1468. [[CrossRef](#)] [[PubMed](#)]
56. Panthong, A.; Kanjanapothi, D.; Niwatananant, W.; Tuntiwachwuttikul, P.; Reutrakul, V. Anti-inflammatory activity of compound D {(E)-4-(3',4'-dimethoxyphenyl)but-3-en-2-ol} isolated from *Zingiber cassumunar* Roxb. *Phytomedicine* **1997**, *4*, 207–212. [[CrossRef](#)]
57. Chaiyana, W.; Anuchapreeda, S.; Leelapornpisid, P.; Phongpradist, R.; Viernstein, H.; Mueller, M. Development of microemulsion delivery system of essential oil from *Zingiber cassumunar* Roxb. rhizome for improvement of stability and anti-inflammatory activity. *AAPS PharmSciTech* **2017**, *18*, 1332–1342. [[CrossRef](#)]
58. Jiang, H.; Xie, Z.; Koo, H.J.; McLaughlin, S.P.; Timmermann, B.N.; Gang, D.R. Metabolic profiling and phylogenetic analysis of medicinal *Zingiber* species: Tools for authentication of ginger (*Zingiber officinale* Rosc.). *Phytochemistry* **2006**, *67*, 1673–1685. [[CrossRef](#)] [[PubMed](#)]
59. Jantan, I.b.; Yassin, M.S.M.; Chin, C.B.; Chen, L.L.; Sim, N.L. Antifungal Activity of the Essential Oils of Nine Zingiberaceae Species. *Pharm. Biol.* **2003**, *41*, 392–397. [[CrossRef](#)]
60. Crop, T.F.; Thammarat, N.S. Screening for Plant Extract, Antagonistic Microorganism and Fungicides to Control *Ganoderma boninense* Caused Stem Rot of Oil Palm in Vitro. *Int. J. Agric. Technol.* **2017**, *13*, 141–147.
61. Tripathi, P.; Dubey, N.K.; Shukla, A.K. Use of some essential oils as post-harvest botanical fungicides in the management of grey mould of grapes caused by *Botrytis cinerea*. *World J. Microbiol. Biotechnol.* **2008**, *24*, 39–46. [[CrossRef](#)]
62. Sharma, G.J.; Chirangini, Z.A.; Mishra, K.P. Evaluation of antioxidant and cytotoxic properties of tropical ginger, *Zingiber montanum* (J. Konig) A Dietr. *Gard. Bull. Singap.* **2007**, *59*, 189–202.
63. Indrianingsih, A.W.; Prihantini, A.I.; Indrianingsih, A.W.; Prihantini, A.I. In vitro antioxidant and α -glucosidase inhibitory assay of *Zingiber cassumunar* roxb. In *AIP Conference Proceedings*; AIP Publishing LLC: Melville, NY, USA, 2018; Volume 2026, p. 20005.
64. Masuda, T.; Jitoe, A. Antioxidative and Antiinflammatory Compounds from Tropical Gingers: Isolation, Structure Determination, and Activities of Cassumunins A, B, and C, New Complex Curcuminoids from *Zingiber cassumunar*. *J. Agric. Food Chem.* **1994**, *42*, 1850–1856. [[CrossRef](#)]
65. Bua-in, S.; Paisooksantivatana, Y. Essential Oil and Antioxidant Activity of Cassumunar Ginger (Zingiberaceae: *Zingiber montanum* (Koenig) Link ex Dietr.) Collected from Various Parts of Thailand. *Kasetsart J. (Nat. Sci.)* **2009**, *43*, 467–475.
66. Jena, A.K.; Sahoo, R.K.; Subudhi, E.; Ghosh, G.; Subudhi, B.B.; Nayak, S. Studies on antioxidant, antimicrobial and phytochemical analysis of *Zingiber capitatum* roxb. Rhizome extracts. *Int. J. Integr. Biol.* **2011**, *11*, 127–133.
67. Boonyanugomol, W.; Kraisriwattana, K.; Rukseree, K.; Boonsam, K.; Narachai, P. In vitro synergistic antibacterial activity of the essential oil from *Zingiber cassumunar* Roxb against extensively drug-resistant *Acinetobacter baumannii* strains. *J. Infect. Public Health* **2017**, *10*, 586–592. [[CrossRef](#)] [[PubMed](#)]
68. Lamlerthon, S.; Tiyaonchai, W. Antimicrobial activity of essential oils against five strains of *Propionibacterium acnes*. *Mahidol Univ. J. Pharm. Sci.* **2007**, *34*, 60–64.
69. Manimmanakorn, N.; Manimmanakorn, A.; Boobphachart, D.; Thuwakum, W.; Laupattarakasem, W.; Hamlin, M.J. Effects of Plai cream [*Zingiber montanum* (J.Koenig) Link ex A.Dietr. syn. *Zingiber cassumunar* Roxb.] combined with ultrasound on delayed muscle soreness. *Indian J. Trait. Knowl.* **2017**, *16*, 442–447.
70. Koparde, A.A.; Magdum, C.S. Analgesic activity of extracts of *Eulophia ochreatea* Lindl. and *Zingiber cassumunar* Roxb. in animal model. *Int. J. Pharm. Sci. Res.* **2018**, *9*, 1956–1962.
71. Yuniarto, A.; Susilawati, E.; Rahman, T.A.; Setiawan, F.; Juanda, D. Gastric Ulcer Healing Effect of Bangle (*Zingiber cassumunar* (Roxb.)) Rhizome Extract in Aspirin-induced Rats Model. *Indones. J. Pharm. Sci. Technol.* **2017**, *1*, 29–34. [[CrossRef](#)]

72. Subhadhirasakul, S.; Tewtrakul, S. Anti-allergic activity of some selected plants in the Zingiberaceae family. *J. Ethnopharmacol.* **2007**, *109*, 535–538.
73. Tanticharoenwiwat, P.; Kulalert, P.; Dechatiwongse Na Ayudhya, T.; Koontongkaew, S.; Jiratchariyakul, W.; Soawakontha, R.; Booncong, P.; Poachanukoon, O. Inhibitory effect of Phlai capsules on skin test responses among allergic rhinitis patients: A randomized, three-way crossover study. *J. Integr. Med.* **2017**, *15*, 462–468. [[CrossRef](#)]
74. Zulkhairi, A.M.; Aspollah, S.M.; Lian, E.G.C.; Bustamam, A.A. Phytochemicals and cytotoxic studies of *Zingiber cassumunar* Roxb. *J. Trop. Agric. Fd. Sc.* **2017**, *45*, 187–197.
75. Dulpinijthamma, J.; Poachanukoon, O.; Saiphoklang, N. The effect of *Zingiber cassumunar* (Phlai capsule) on bronchial hyperresponsiveness in asthmatic patients. *J. Allergy Clin. Immunol.* **2020**, *145*, AB20. [[CrossRef](#)]
76. Limvuttgrijerat, T.; Poachanukoon, O.; Koontongkaew, S.; Ayudhya, T.D.N. Crude ethanolic extracts of *Zingiber cassumunar* ROXB. inhibit PMA-induced MUC2 and MUC5AC expression via ERK inhibition in human airway epithelial cells. *Asian Pac. J. Allergy Immunol.* **2014**, *32*, 328.
77. Bandara, K.A.N.P.; Kumar, V.; Saxena, R.C.; Ramdas, P.K. Bruchid (Coleoptera: Bruchidae) ovicidal phenylbutanoid from *Zingiber purpureum*. *J. Econ. Entomol.* **2005**, *98*, 1163–1169. [[CrossRef](#)]
78. Okonogi, S.; Chaiyana, W. Enhancement of anti-cholinesterase activity of *Zingiber cassumunar* essential oil using a microemulsion technique. *Drug Discov. Ther.* **2012**, *6*, 249–255. [[CrossRef](#)]
79. Dev, S. Studies in sesquiterpenes-XVI. Zerumbone, a monocyclic sesquiterpene ketone. *Tetrahedron* **1960**, *8*, 171–180. [[CrossRef](#)]
80. Kitayama, T.; Okamoto, T.; Hill, R.K.; Kawai, Y.; Takahashi, S.; Yonemori, S.; Yamamoto, Y.; Ohe, K.; Uemura, S.; Sawada, S. Chemistry of Zerumbone. 1. Simplified isolation, conjugate addition reactions, and a unique ring contracting transannular reaction of its dibromide. *J. Org. Chem.* **1999**, *64*, 2667–2672. [[CrossRef](#)] [[PubMed](#)]
81. Masuda, T.; Jitoe, A.; Kato, S.; Nakatani, N. Acetylated flavonol glycosides from *Zingiber zerumbet*. *Phytochemistry* **1991**, *30*, 2391–2392. [[CrossRef](#)]
82. Chien, T.Y.; Chen, L.G.; Lee, C.J.; Lee, F.Y.; Wang, C.C. Anti-inflammatory constituents of *Zingiber zerumbet*. *Food Chem.* **2008**, *110*, 584–589. [[CrossRef](#)]
83. Ruslay, S.; Abas, F.; Shaari, K.; Zainal, Z.; Maulidiani, Sirat, H.; Israf, D.A.; Lajis, N.H. Characterization of the components present in the active fractions of health gingers (*Curcuma xanthorrhiza* and *Zingiber zerumbet*) by HPLC-DAD-ESIMS. *Food Chem.* **2007**, *104*, 1183–1191. [[CrossRef](#)]
84. Dai, J.R.; Cardellina, J.H.; McMahon, J.B.; Boyd, M.R. Zerumbone, an HIV-inhibitory and cytotoxic sesquiterpene of *Zingiber aromaticum* and *Z. zerumbet*. *Nat. Prod. Lett.* **1997**, *10*, 115–118. [[CrossRef](#)]
85. Rahman, H.S.; Rasedee, A.; Yeap, S.K.; Othman, H.H.; Chartrand, M.S.; Namvar, F.; Abdul, A.B.; How, C.W. Biomedical properties of a natural dietary plant metabolite, zerumbone, in cancer therapy and chemoprevention trials. *BioMed Res. Int.* **2014**, *2014*, 920742. [[CrossRef](#)] [[PubMed](#)]
86. Sadhu, S.K.; Khatun, A.; Ohtsuki, T.; Ishibashi, M. First isolation of sesquiterpenes and flavonoids from *Zingiber spectabile* and identification of zerumbone as the major cell growth inhibitory component. *Nat. Prod. Res.* **2007**, *21*, 1242–1247. [[CrossRef](#)]
87. Kalantari, K.; Moniri, M.; Moghaddam, A.B.; Rahim, R.A.; Ariff, A.B.; Izadiyan, Z.; Mohamad, R. A Review of the biomedical applications of zerumbone and the techniques for its extraction from ginger rhizomes. *Molecules* **2017**, *22*, 1645. [[CrossRef](#)]
88. Sehwat, A.; Sakao, K.; Singh, S.V. Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells. *Breast Cancer Res. Treat.* **2014**, *146*, 543–555. [[CrossRef](#)] [[PubMed](#)]
89. Shin, J.W.; Ohnishi, K.; Murakami, A.; Lee, J.S.; Kundu, J.K.; Na, H.K.; Ohigashi, H.; Surh, Y.J. Zerumbone induces heme oxygenase-1 expression in mouse skin and cultured murine epidermal cells through activation of Nrf2. *Cancer Prev. Res.* **2011**, *4*, 860–870. [[CrossRef](#)]
90. Saranya, J.; Dhanya, B.P.; Greeshma, G.; Radhakrishnan, K.V.; Priya, S. Effects of a new synthetic zerumbone pendant derivative (ZPD) on apoptosis induction and anti-migratory effects in human cervical cancer cells. *Chem. Biol. Interact.* **2017**, *278*, 32–39. [[CrossRef](#)]
91. Agide, F.D.; Sadeghi, R.; Garmaroudi, G.; Tigabu, B.M. A systematic review of health promotion interventions to increase breast cancer screening uptake: From the last 12 years. *Eur. J. Public Health* **2018**, *28*, 1149–1155. [[CrossRef](#)]
92. Ashraf, S.M.; Sebastian, J.; Rathinasamy, K. Zerumbone, a cyclic sesquiterpene, exerts antimitotic activity in HeLa cells through tubulin binding and exhibits synergistic activity with vinblastine and paclitaxel. *Cell Prolif.* **2019**, *52*, e12558. [[CrossRef](#)] [[PubMed](#)]
93. Rosa, A.; Caprioglio, D.; Isola, R.; Nieddu, M.; Appendino, G.; Falchi, A.M. Dietary zerumbone from shampoo ginger: New insights into its antioxidant and anticancer activity. *Food Funct.* **2019**, *10*, 1629–1642. [[CrossRef](#)]
94. Utaka, Y.; Kashiwazaki, G.; Tajima, S.; Fujiwara, Y.; Sumi, K.; Itoh, T.; Kitayama, T. Antiproliferative effects of zerumbone-pendant derivatives on human T-cell lymphoid cell line Jurkat cells. *Tetrahedron* **2019**, *75*, 1343–1350. [[CrossRef](#)]
95. Wang, M.; Niu, J.; Gao, L.; Gao, Y.; Gao, S. Zerumbone inhibits migration in ESCC via promoting Rac1 ubiquitination. *Biomed. Pharmacother.* **2019**, *109*, 2447–2455. [[CrossRef](#)] [[PubMed](#)]
96. Mohamad, N.E.; Abu, N.; Rahman, H.S.; Ky, H.; Ho, W.Y.; Lim, K.L.; How, C.W.; Rasedee, A.; Alitheen, N.B.; Yeap, S.K. Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice. *RSC Adv.* **2015**, *5*, 22066–22074. [[CrossRef](#)]

97. Sithara, T.; Dhanya, B.P.; Arun, K.B.; Sini, S.; Dan, M.; Kokkuvayil Vasu, R.; Nisha, P. Zerumbone, a Cyclic Sesquiterpene from *Zingiber zerumbet* Induces Apoptosis, Cell Cycle Arrest, and Antimigratory Effects in SW480 Colorectal Cancer Cells. *J. Agric. Food Chem.* **2018**, *66*, 602–612. [[CrossRef](#)]
98. Tan, J.W.; Israf, D.A.; Tham, C.L. Major bioactive compounds in essential oils extracted from the rhizomes of *Zingiber zerumbet* (L.) Smith: A mini-review on the anti-allergic and immunomodulatory properties. *Front. Pharmacol.* **2018**, *9*, 652. [[CrossRef](#)] [[PubMed](#)]
99. Eid, E.E.M.; Azam, F.; Hassan, M.; Taban, I.M.; Halim, M.A. Zerumbone binding to estrogen receptors: An in-silico investigation. *J. Recept. Signal. Transduct.* **2018**, *38*, 342–351. [[CrossRef](#)]
100. Abdel Wahab, S.I.; Abdul, A.B.; Alzubairi, A.S.; Mohamed Elhassan, M.; Mohan, S. In Vitro Ultramorphological Assessment of Apoptosis Induced by Zerumbone on (HeLa). *J. Biomed. Biotechnol.* **2009**, *2009*, 769568. [[CrossRef](#)]
101. Kang, C.G.; Lee, H.-J.; Kim, S.-H.; Lee, E.-O. Zerumbone Suppresses Osteopontin-Induced Cell Invasion Through Inhibiting the FAK/AKT/ROCK Pathway in Human Non-Small Cell Lung Cancer A549 Cells. *J. Nat. Prod.* **2016**, *79*, 156–160. [[CrossRef](#)]
102. Hu, Z.; Zeng, Q.; Zhang, B.; Liu, H.; Wang, W. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells. *Biochimie* **2014**, *107*, 257–262. [[CrossRef](#)] [[PubMed](#)]
103. Jorvig, J.E.; Chakraborty, A. Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity. *Anticancer. Drugs* **2015**, *26*, 160–166. [[CrossRef](#)]
104. Jeon, M.; Han, J.; Nam, S.J.; Lee, J.E.; Kim, S. Elevated IL-1 β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone. *Chem. Biol. Interact.* **2016**, *258*, 126–133. [[CrossRef](#)]
105. Hosseini, N.; Khoshnazar, A.; Saidijam, M.; Azizi Jalilian, F.; Najafi, R.; Mahdavinzhad, A.; Ezati, R.; Sotanian, A.; Amini, R. Zerumbone Suppresses Human Colorectal Cancer Invasion and Metastasis via Modulation of FAK/PI3k/NF κ B-uPA Pathway. *Nutr. Cancer* **2019**, *71*, 159–171. [[CrossRef](#)] [[PubMed](#)]
106. Huang, G.C.; Chien, T.Y.; Chen, L.G.; Wang, C.C. Antitumor effects of zerumbone from *Zingiber zerumbet* in P-388D1 cells in vitro and in vivo. *Planta Med.* **2005**, *71*, 219–224. [[CrossRef](#)]
107. Zhang, S.; Liu, Q.; Liu, Y.; Qiao, H.; Liu, Y. Zerumbone, a Southeast Asian ginger sesquiterpene, induced apoptosis of pancreatic carcinoma cells through p53 signaling pathway. *Evid.-Based Complement. Altern. Med.* **2012**, *2012*, 936030. [[CrossRef](#)] [[PubMed](#)]
108. Eid, E.E.M.; Alanazi, A.S.; Koosha, S.; Alrasheedy, A.A.; Azam, F.; Taban, I.M.; Khalilullah, H.; Sadiq Al-Qubaisi, M.; Alshawsh, M.A. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting α v β 3 Integrin upon Co-Administration with TP5-iRGD Peptide. *Molecules* **2019**, *24*, 2554. [[CrossRef](#)]
109. Abdelwahab, S.I.; Abdul, A.B.; Mohan, S.; Taha, M.M.E.; Syam, S.; Ibrahim, M.Y.; Mariod, A.A. Zerumbone induces apoptosis in T-acute lymphoblastic leukemia cells. *Leuk. Res.* **2011**, *35*, 268–271. [[CrossRef](#)] [[PubMed](#)]
110. Chan, M.-L.; Liang, J.-W.; Hsu, L.-C.; Chang, W.-L.; Lee, S.-S.; Guh, J.-H. Zerumbone, a ginger sesquiterpene, induces apoptosis and autophagy in human hormone-refractory prostate cancers through tubulin binding and crosstalk between endoplasmic reticulum stress and mitochondrial insult. *Naunyn. Schmiedeberg's Arch. Pharmacol.* **2015**, *388*, 1223–1236. [[CrossRef](#)] [[PubMed](#)]
111. Dermani, F.K.; Amini, R.; Saidijam, M.; Pourjafar, M.; Saki, S.; Najafi, R. Zerumbone inhibits epithelial-mesenchymal transition and cancer stem cells properties by inhibiting the β -catenin pathway through miR-200c. *J. Cell. Physiol.* **2018**, *233*, 9538–9547. [[CrossRef](#)]
112. Ma, S.; Lei, Y.; Zhang, L.; Wang, J. Effects of zerumbone on proliferation and apoptosis of esophageal cancer cells and on P53 and Bcl-2 expression levels. *Oncol. Lett.* **2018**, *16*, 4379–4383. [[CrossRef](#)]
113. Murakami, A. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: The alpha, beta-unsaturated carbonyl group is a prerequisite. *Carcinogenesis* **2002**, *23*, 795–802. [[CrossRef](#)]
114. Kim, S.; Kil, W.H.; Lee, J.; Oh, S.-J.; Han, J.; Jeon, M.; Jung, T.; Lee, S.K.; Bae, S.Y.; Lee, H.C. Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells. *Oncol. Rep.* **2014**, *32*, 2666–2672. [[CrossRef](#)] [[PubMed](#)]
115. Kim, S.; Lee, J.; Jeon, M.; Lee, J.E.; Nam, S.J. Zerumbone suppresses the motility and tumorigenicity of triple negative breast cancer cells via the inhibition of TGF- β 1 signaling pathway. *Oncotarget* **2016**, *7*, 1544. [[CrossRef](#)] [[PubMed](#)]
116. Lv, T.; Zhang, W.; Han, X. Zerumbone suppresses the potential of growth and metastasis in hepatoma HepG2 cells via the MAPK signaling pathway. *Oncol. Lett.* **2018**, *15*, 7603–7610. [[CrossRef](#)] [[PubMed](#)]
117. Jegannathan, S.D.; Arul, S.; Dayalan, H. Zerumbone, a Sesquiterpene, Controls Proliferation and Induces Cell Cycle Arrest in Human Laryngeal Carcinoma Cell Line Hep-2. *Nutr. Cancer* **2016**, *68*, 865–872. [[CrossRef](#)]
118. Kim, M.; Miyamoto, S.; Yasui, Y.; Oyama, T.; Murakami, A.; Tanaka, T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. *Int. J. Cancer* **2009**, *124*, 264–271. [[CrossRef](#)]
119. Abdelwahab, S.I.; Abdul, A.B.; Devi, N.; Ehasan Taha, M.M.; Al-zubairi, A.S.; Mohan, S.; Mariod, A.A. Regression of cervical intraepithelial neoplasia by zerumbone in female Balb/c mice prenatally exposed to diethylstilboestrol: Involvement of mitochondria-regulated apoptosis. *Exp. Toxicol. Pathol.* **2010**, *62*, 461–469. [[CrossRef](#)]
120. Abdelwahab, S.I.; Abdul, A.B.; Zain, Z.N.M.; Hadi, A.H.A. Zerumbone inhibits interleukin-6 and induces apoptosis and cell cycle arrest in ovarian and cervical cancer cells. *Int. Immunopharmacol.* **2012**, *12*, 594–602. [[CrossRef](#)]
121. Abdul, A.B.; Abdelwahab, S.I.; Jalinias, J.B.; Al-Zubairi, A.S.; Taha, M.M.E. Combination of zerumbone and cisplatin to treat cervical intraepithelial neoplasia in female BALB/c mice. *Int. J. Gynecol. Cancer* **2009**, *19*, 1004–1010. [[CrossRef](#)]
122. Abdul, A.B.; Abdelwahab, S.I.; Al-Zubaira, A.S.; Elhassan, M.M.; Murali, S.M. Anticancer and antimicrobial activities of zerumbone from the rhizomes of *Zingiber zerumbet*. *Int. J. Pharmacol.* **2008**, *4*, 301–304. [[CrossRef](#)]

123. Abdul, A.B.H.; Al-Zubairi, A.S.; Tailan, N.D.; Wahab, S.I.A.; Zain, Z.N.M.; Rusley, S.; Syam, M.M. Anticancer activity of natural compound (Zerumbone) extracted from Zingiber zerumbet in human HeLa cervical cancer cells. *Int. J. Pharmacol.* **2008**, *4*, 160–168.
124. Sakinah, S.A.S.; Tri Handayani, S.; Hawariah, L.P.A. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. *Cancer Cell Int.* **2007**, *7*, 4. [[CrossRef](#)]
125. Al-Amin, M.; Eltayeb, N.M.; Khairuddean, M.; Salhimi, S.M. Bioactive chemical constituents from Curcuma caesia Roxb. rhizomes and inhibitory effect of curcuzederone on the migration of triple-negative breast cancer cell line MDA-MB-231. *Nat. Prod. Res.* **2019**, 3166–3170. [[CrossRef](#)] [[PubMed](#)]
126. Samad, N.A.; Abdul, A.B.; Rahman, H.S.; Rasedee, A.; Ibrahim, T.A.T.; Keon, Y.S. Zerumbone suppresses angiogenesis in HepG2 cells through inhibition of matrix metalloproteinase-9, vascular endothelial growth factor, and vascular endothelial growth factor receptor expressions. *Pharmacogn. Mag.* **2017**, *13*, S731.
127. Sehwat, A.; Arlotti, J.A.; Murakami, A.; Singh, S.V. Zerumbone causes Bax- and Bak-mediated apoptosis in human breast cancer cells and inhibits orthotopic xenograft growth in vivo. *Breast Cancer Res. Treat.* **2012**, *136*, 429–441. [[CrossRef](#)]
128. Shamoto, T.; Matsuo, Y.; Shibata, T.; Tsuboi, K.; Nagasaki, T.; Takahashi, H.; Funahashi, H.; Okada, Y.; Takeyama, H. Zerumbone inhibits angiogenesis by blocking NF- κ B activity in pancreatic cancer. *Pancreas* **2014**, *43*, 396–404. [[CrossRef](#)]
129. Shanmugam, M.K.; Rajendran, P.; Li, F.; Kim, C.; Sikka, S.; Siveen, K.S.; Kumar, A.P.; Ahn, K.S.; Sethi, G. Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model. *Mol. Carcinog.* **2015**, *54*, 971–985. [[CrossRef](#)]
130. Zainal, N.S.; Gan, C.P.; Lau, B.F.; Yee, P.S.; Tiong, K.H.; Abdul Rahman, Z.A.; Patel, V.; Cheong, S.C. Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells. *Phytomedicine* **2018**, *39*, 33–41. [[CrossRef](#)] [[PubMed](#)]
131. Shyanti, R.K.; Sehwat, A.; Singh, S.V.; Mishra, J.P.N.; Singh, R.P. Zerumbone modulates CD1d expression and lipid antigen presentation pathway in breast cancer cells. *Toxicol. Vitr.* **2017**, *44*, 74–84. [[CrossRef](#)]
132. Rahman, H.S.; Rasedee, A.; How, C.W.; Zeenathul, N.A.; Chartrand, M.S.; Yeap, S.K.; Abdul, A.B.; Tan, S.W.; Othman, H.H.; Ajdari, Z. Antileukemic effect of zerumbone-loaded nanostructured lipid carrier in WEHI-3B cell-induced murine leukemia model. *Int. J. Nanomed.* **2015**, *10*, 1649. [[CrossRef](#)]
133. Wang, D.; Li, Y.; Cui, P.; Zhao, Q.; Tan, B.; Zhang, Z.; Liu, Y.; Jia, N. Zerumbone induces gastric cancer cells apoptosis: Involving cyclophilin A. *Biomed. Pharmacother.* **2016**, *83*, 740–745. [[CrossRef](#)]
134. Wani, N.A.; Zhang, B.; Teng, K.; Barajas, J.M.; Motiwala, T.; Hu, P.; Yu, L.; Brüscheiler, R.; Ghoshal, K.; Jacob, S.T. Reprograming of glucose metabolism by zerumbone suppresses hepatocarcinogenesis. *Mol. Cancer Res.* **2018**, *16*, 256–268. [[CrossRef](#)]
135. Weng, H.-Y.; Hsu, M.-J.; Wang, C.-C.; Chen, B.-C.; Hong, C.-Y.; Chen, M.-C.; Chiu, W.-T.; Lin, C.-H. Zerumbone suppresses IKK α , Akt, and FOXO1 activation, resulting in apoptosis of GBM 8401 cells. *J. Biomed. Sci.* **2012**, *19*, 86. [[CrossRef](#)]
136. Yan, H.; Ren, M.; Wang, Z.; Feng, S.; Li, S.; Cheng, Y.; Hu, C.; Gao, S.; Zhang, G. Zerumbone inhibits melanoma cell proliferation and migration by altering mitochondrial functions. *Oncol. Lett.* **2017**, *13*, 2397–2402. [[CrossRef](#)]
137. Rajan, I.; Jayasree, P.R.; Kumar, P.R.M. Zerumbone induces mitochondria-mediated apoptosis via increased calcium, generation of reactive oxygen species and upregulation of soluble histone H2AX in K562 chronic myelogenous leukemia cells. *Tumor Biol.* **2015**, *36*, 8479–8489. [[CrossRef](#)] [[PubMed](#)]
138. Kim, M.J.; Yun, J.M. Molecular mechanism of the protective effect of zerumbone on lipopolysaccharide-induced inflammation of THP-1 cell-derived macrophages. *J. Med. Food* **2019**, *22*, 62–73. [[CrossRef](#)]
139. Ho, Y.C.; Lee, S.S.; Yang, M.L.; Huang-Liu, R.; Lee, C.Y.; Li, Y.C.; Kuan, Y.H. Zerumbone reduced the inflammatory response of acute lung injury in endotoxin-treated mice via Akt-NF κ B pathway. *Chem. Biol. Interact.* **2017**, *271*, 9–14. [[CrossRef](#)] [[PubMed](#)]
140. Somchit, M.N.; Mak, J.H.; Bustamam, A.A.; Zuraini, A.; Arifah, A.K.; Adam, Y.; Zakaria, Z.A. Zerumbone isolated from Zingiber zerumbet inhibits inflammation and pain in rats. *J. Med. Plants Res.* **2012**, *6*, 177–180. [[CrossRef](#)]
141. Igarashi, Y.; Ohnishi, K.; Irie, K.; Murakami, A. Possible contribution of zerumbone-induced proteo-stress to its anti-inflammatory functions via the activation of heat shock factor 1. *PLoS ONE* **2016**, *11*, e0161282. [[CrossRef](#)]
142. Hwang, S.; Jo, M.; Hong, E.J.; Park, O.C.; Lee, G.C.; Yun, M.; Rhee, K.-J. Zerumbone Suppresses Enterotoxigenic Bacteroides fragilis Infection-Induced Colonic Inflammation through Inhibition of NF- κ B. *Int. J. Mol. Sci.* **2019**, *20*, 4560. [[CrossRef](#)] [[PubMed](#)]
143. Haque, M.A.; Jantan, I.; Harikrishnan, H. Zerumbone suppresses the activation of inflammatory mediators in LPS-stimulated U937 macrophages through MyD88-dependent NF- κ B/MAPK/PI3K-Akt signaling pathways. *Int. Immunopharmacol.* **2018**, *55*, 312–322. [[CrossRef](#)] [[PubMed](#)]
144. Lee, C.-Y.; Chen, S.-P.; Su, C.-H.; Ho, Y.-C.; Yang, M.-L.; Lee, S.-S.; Huang, L.R.; Yang, C.-P.; Chan, C.J.; Kuan, Y.-H. Zerumbone from Zingiber zerumbet ameliorates lipopolysaccharide-induced ICAM-1 and cytokines expression via p38 MAPK/JNK-I κ B/NF- κ B pathway in mouse model of acute lung injury. *Chin. J. Physiol.* **2018**, *61*, 171–180. [[CrossRef](#)] [[PubMed](#)]
145. Leung, W.-S.; Yang, M.-L.; Lee, S.-S.; Kuo, C.-W.; Ho, Y.-C.; Huang-Liu, R.; Lin, H.-W.; Kuan, Y.-H. Protective effect of zerumbone reduces lipopolysaccharide-induced acute lung injury via antioxidative enzymes and Nrf2/HO-1 pathway. *Int. Immunopharmacol.* **2017**, *46*, 194–200. [[CrossRef](#)]
146. Murakami, A.; Matsumoto, K.; Koshimizu, K.; Ohigashi, H. Effects of selected food factors with chemopreventive properties on combined lipopolysaccharide- and interferon- γ -induced I κ B degradation in RAW264.7 macrophages. *Cancer Lett.* **2003**, *195*, 17–25. [[CrossRef](#)]

147. Murakami, A.; Shigemori, T.; Ohigashi, H. Zingiberaceous and citrus constituents, 1'-acetoxychavicol acetate, zerumbone, auraptene, and nobiletin, suppress lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264. 7 murine macrophages through different modes of action. *J. Nutr.* **2005**, *135*, 2987S–2992S. [[CrossRef](#)]
148. Rücker, H.; Amslinger, S. Identification of heme oxygenase-1 stimulators by a convenient ELISA-based bilirubin quantification assay. *Free Radic. Biol. Med.* **2015**, *78*, 135–146. [[CrossRef](#)]
149. Vishwanatha, H.N.; Niraguna Babu, P.; Gowrishankar, B.S.; Sridhar, S.B. Antimicrobial activity of zerumbone from *Zingiber zerumbet* against *Staphylococcus epidermidis* and *Aspergillus* sp. *Int. J. Appl. Biol. Pharm. Tech.* **2012**, *3*, 40–43.
150. Kim, H.R.; Rhee, K.J.; Eom, Y. Bin Anti-biofilm and antimicrobial effects of zerumbone against *Bacteroides fragilis*. *Anaerobe* **2019**, *57*, 99–106. [[CrossRef](#)]
151. Moreira Da Silva, T.; Pinheiro, C.D.; Puccinelli Orlandi, P.; Pinheiro, C.C.; Soares Pontes, G. Zerumbone from *Zingiber zerumbet* (L.) smith: A potential prophylactic and therapeutic agent against the cariogenic bacterium *Streptococcus mutans*. *BMC Complement. Altern. Med.* **2018**, *18*, 1–9. [[CrossRef](#)] [[PubMed](#)]
152. Kitayama, T.; Yamamoto, K.; Utsumi, R.; Takatani, M.; Hill, R.K.; Kawai, Y.; Sawada, S.; Okamoto, T. Chemistry of zerumbone. 2. Regulation of ring bond cleavage and unique antibacterial activities of zerumbone derivatives. *Biosci. Biotechnol. Biochem.* **2001**, *65*, 2193–2199. [[CrossRef](#)] [[PubMed](#)]
153. Keong, Y.S.; Alitheen, N.B.; Mustafa, S.; Aziz, S.A.; Rahman, M.A.; Ali, A.M. Immunomodulatory effects of zerumbone isolated from roots of *Zingiber zerumbet*. *Pak. J. Pharm. Sci.* **2010**, *23*, 75–82. [[PubMed](#)]
154. Dash, S.; Ray, M.; Mishra, A.; Shahbazi, S.; Gopinath Achary, A.; Nayak, S.; Singh, S. Zerumbone, a natural plant dietary compound induces expression of interleukin-12p70 cytokine in human peripheral blood mononuclear cells. *Asian J. Pharm. Clin. Res.* **2016**, *9*, 312–315. [[CrossRef](#)]
155. Hamdi, O.A.A.; Ye, L.J.; Kamarudin, M.N.A.; Hazni, H.; Paydar, M.; Looi, C.Y.; Shilpi, J.A.; Kadir, H.A.; Awang, K. Neuroprotective and antioxidant constituents from *Curcuma zedoaria* Rhizomes. *Rec. Nat. Prod.* **2015**, *9*, 349–355.
156. Gopalsamy, B.; Farouk, A.A.O.; Tengku Mohamad, T.A.S.; Sulaiman, M.R.; Perimal, E.K. Antiallodynic and antihyperalgesic activities of zerumbone via the suppression of IL-1 β , IL-6, and TNF- α in a mouse model of neuropathic pain. *J. Pain Res.* **2017**, *10*, 2605–2619. [[CrossRef](#)]
157. Jantan, I.; Raweh, S.M.; Sirat, H.M.; Jamil, S.; Mohd Yasin, Y.H.; Jalil, J.; Jamal, J.A. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation. *Phytomedicine* **2008**, *15*, 306–309. [[CrossRef](#)]
158. Oh, T.I.; Jung, H.J.; Lee, Y.M.; Lee, S.; Kim, G.H.; Kan, S.Y.; Kang, H.; Oh, T.; Ko, H.M.; Kwak, K.C.; et al. Zerumbone, a tropical ginger sesquiterpene of *Zingiber officinale* Roscoe, attenuates α -MSH-induced melanogenesis in B16F10 cells. *Int. J. Mol. Sci.* **2018**, *19*, 3149. [[CrossRef](#)] [[PubMed](#)]
159. Kim, J.W.; Yang, D.; Jeong, H.; Park, I.S.; Lee, M.H.; Lim, C.W.; Kim, B. Dietary zerumbone, a sesquiterpene, ameliorates hepatotoxin-mediated acute and chronic liver injury in mice. *Phyther. Res.* **2019**, *33*, 1538–1550. [[CrossRef](#)] [[PubMed](#)]
160. Wang, M.; Niu, J.; Ou, L.; Deng, B.; Wang, Y.; Li, S. Zerumbone protects against carbon tetrachloride (CCl₄)-induced acute liver injury in mice via inhibiting oxidative stress and the inflammatory response: Involving the TLR4/NF- κ B/COX-2 pathway. *Molecules* **2019**, *24*, 1964. [[CrossRef](#)] [[PubMed](#)]
161. Hamid, A.; Lee, L.S.; Karim, S.R.; Jufri, N.F. Hepatoprotective effects of zerumbone against paracetamol-induced acute hepatotoxicity in rats. *Malays. J. Med. Sci. MJMS* **2018**, *25*, 64. [[CrossRef](#)] [[PubMed](#)]
162. Ghazalee, N.S.; Jantan, I.; Arshad, L.; Haque, M.A. Immunosuppressive effects of the standardized extract of *Zingiber zerumbet* on innate immune responses in Wistar rats. *Phyther. Res.* **2019**, *33*, 929–938. [[CrossRef](#)]
163. Akhtar, N.M.Y.; Jantan, I.; Arshad, L.; Haque, M.A. Standardized ethanol extract, essential oil and zerumbone of *Zingiber zerumbet* rhizome suppress phagocytic activity of human neutrophils. *BMC Complement. Altern. Med.* **2019**, *19*, 331. [[CrossRef](#)] [[PubMed](#)]
164. Shieh, Y.H.; Huang, H.M.; Wang, C.C.; Lee, C.C.; Fan, C.K.; Lee, Y.L. Zerumbone enhances the Th1 response and ameliorates ovalbumin-induced Th2 responses and airway inflammation in mice. *Int. Immunopharmacol.* **2015**, *24*, 383–391. [[CrossRef](#)] [[PubMed](#)]
165. Albaayit, S.F.A.; Maharjan, R.; Liao, J.W.; Rajendran, P.; Wu, J.J.; Hseu, Y.C. Immunomodulation of Zerumbone via Decreasing the Production of Reactive Oxygen Species from Immune Cells. *Science* **2018**, *21*, 475–479.
166. Hemn, H.O. Influence of Zerumbone Supplementation a Natural Dietary Product from *Zingiber zerumbet* smith on Early-Developed Atherosclerotic Lesions in Cholesterol-Fed Rabbits. *Open Conf. Proc. J.* **2014**, *4*, 61–64. [[CrossRef](#)]
167. Tzeng, T.F.; Lu, H.J.; Liou, S.S.; Chang, C.J.; Liu, I.M. Lipid-lowering effects of zerumbone, a natural cyclic sesquiterpene of *Zingiber zerumbet* Smith, in high-fat diet-induced hyperlipidemic hamsters. *Food Chem. Toxicol.* **2014**, *69*, 132–139. [[CrossRef](#)]
168. Ahn, J.; Lee, H.; Jung, C.H.; Choi, W.H.; Ha, T.Y. Zerumbone ameliorates high-fat diet-induced adiposity by restoring AMPK-regulated lipogenesis and microRNA-146b/SIRT1-mediated adipogenesis. *Oncotarget* **2017**, *8*, 36984. [[CrossRef](#)]
169. Beattie, J.H.; Nicol, F.; Gordon, M.-J.; Reid, M.D.; Cantlay, L.; Horgan, G.W.; Kwun, I.-S.; Ahn, J.-Y.; Ha, T.-Y. Ginger phytochemicals mitigate the obesogenic effects of a high-fat diet in mice: A proteomic and biomarker network analysis. *Mol. Nutr. Food Res.* **2011**, *55*, S203–S213. [[CrossRef](#)]
170. Shrikanth, C.B.; Chilkunda, N.D. Zerumbone Ameliorates High Glucose-Induced Reduction in AMP-Activated Protein Kinase Phosphorylation in Tubular Kidney Cells. *J. Agric. Food Chem.* **2017**, *65*, 9208–9216. [[CrossRef](#)] [[PubMed](#)]
171. Tzeng, T.-F.; Liou, S.-S.; Chang, C.J.; Liu, I.-M. Zerumbone, a tropical ginger sesquiterpene, ameliorates streptozotocin-induced diabetic nephropathy in rats by reducing the hyperglycemia-induced inflammatory response. *Nutr. Metab.* **2013**, *10*, 64. [[CrossRef](#)]

172. Tzeng, T.-F.; Liou, S.-S.; Tzeng, Y.-C.; Liu, I.-M. Zerumbone, a Phytochemical of Subtropical Ginger, Protects against Hyperglycemia-Induced Retinal Damage in Experimental Diabetic Rats. *Nutrients* **2016**, *8*, 449. [[CrossRef](#)] [[PubMed](#)]
173. Wang, C.; Zou, S.; Cui, Z.; Guo, P.; Meng, Q.; Shi, X.; Gao, Y.; Yang, G.; Han, Z. Zerumbone protects INS-1 rat pancreatic beta cells from high glucose-induced apoptosis through generation of reactive oxygen species. *Biochem. Biophys. Res. Commun.* **2015**, *460*, 205–209. [[CrossRef](#)] [[PubMed](#)]
174. Liu, W.Y.; Tzeng, T.-F.; Liu, I.-M. Healing potential of zerumbone ointment on experimental full-thickness excision cutaneous wounds in rat. *J. Tissue Viability* **2017**, *26*, 202–207. [[CrossRef](#)] [[PubMed](#)]
175. Eid, E.E.M.; Abdul, A.B.; Suliman, F.E.O.; Sukari, M.A.; Rasedee, A.; Fatah, S.S. Characterization of the inclusion complex of zerumbone with hydroxypropyl- β -cyclodextrin. *Carbohydr. Polym.* **2011**, *83*, 1707–1714. [[CrossRef](#)]